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ABSTRACT OF DISSERTATION

THE ROLE OF p53 IN POLYGLUTAMINE EXPANSION INDUCED
NEURODEGENERATION

Polyglutamine expansion disorders are progressive neurodegenerative diseases
that are caused by the pathological expansion of polyglutamine repeats. Huntington’s
disease (HD) is a polyglutamine disorder caused by the expansion of an existing
polyglutamine tract in a novel protein, Huntingtin (Htt). Oxidative stress has been
implicated in the neural dysfunction observed in multiple neurodegenerative conditions
including HD. The tumor suppressor p53 is a multifunctional protein that has roles in
the cell cycle, apoptosis and neurodevelopment. The role of p53 in HD-associated
neurodegeneration has been studied but not fully elucidated, nor has the role of p53 in
oxidative stress toxicity been fully elucidated.
Here I present work that demonstrates polyglutamine expansion induced
alterations to p53 stability, localization, and activity. The transcriptional activity of p53
was found to have a role in oxidative stress mediated as well as polyglutamine
mediated neurotoxicity in vitro. The expression of p53 was also altered in vivo in a
mouse model of HD as well as in HD brain.

Taken together, these data demonstrate a role for p53 in polyglutamine and oxidative
stress toxicity.
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Chapter One
Introduction/Background

Huntington’s disease
Huntington’s disease (HD) is a progressive neurodegenerative disease that
affects about 1 in 20,000 people of European descent (Rubinsztein, 2002). It is
autosomal dominant in nature and was first described in detail in 1872 by George
Huntington. In 1993, the genetic cause of Huntington’s disease (HD) was defined. The
Huntington’s Disease Collaborative Research Group (HDCRG) identified the gene
IT15, located on the short arm of chromosome 4, as the defective gene common to
members of 75 families afflicted with HD. IT15 was found to have 67 exons, and code
for a protein approximately 348 kD in size. This protein was of unknown function and
had no relation to any known gene (HDCRG, 1993). Subsequently named huntingtin,
this gene contains within exon 1, a region of CAG trinucleotide repeats. HD occurs in
individuals who have an unstable genetic insertion of repeating CAG, which code for
glutamine, sequences. Therefore HD is known as a trinucleotide repeat or
polyglutamine expansion disease. Normal individuals have between 9 and 35
glutamines in the polyglutamine domain of the huntingtin gene (htt), whereas greater
than 37 glutamines results in HD. Polyglutamine expansion is a common mutation in at
least 8 other neurodegenerative disorders including spinocerebellar ataxia 1 (SCA1),
and spinal and bulbar muscular atrophy (SBMA) (Koshy et al., 1997; Shahbazian et al.,
2001; Zoghbi et al., 2000). The polyglutamine expanded proteins that cause each of
these diseases are unique to their individual disease, and have no known relationship to
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each other, other than the region of polyglutamine expansion. All of these diseases
result in selective neurodegeneration.
The presence of polyglutamine expansion is thought to cause a deleterious
gain of function in each of the polyglutamine disorders, which then directly causes
increased neurotoxicity. For example, normal huntingtin protein (Htt) is required for
embryonic development (Zeitlin et al., 1995). This toxicity can be rescued by
expression of mutant Htt (Hodgson et al., 1996). Additionally, when wild-type htt is
over-expressed in vitro, cellular toxicity in response to various stimuli is reduced (Ho et
al., 2001; Leavitt et al., 2001). Htt therefore appears to be an essential protein, and
the polyglutamine expansion does not appear to inactivate it (Wellington et al., 1997;
Zoghbi et al., 2000).
Age of onset and severity of HD is inversely proportional to the length of the
polyglutamine expansion, with most affected people displaying symptoms in their 30’s
or 40’s. However, persons with very long polyglutamine repeats suffer early onset HD,
even before the age of 20 (Koshy et al., 1997). People with HD exhibit symptoms of
chorea, or uncontrollable movements such as grimacing, flexing and unflexing of the
fingers, and movement of the shoulders (Zoghbi et al., 2000). Additional symptoms
include slowness of voluntary movements and speech known as bradykinesia (Zoghbi
et al., 2000). The reflex responses in HD patients are not affected. Late stage patients
have difficulty with swallowing and become dystonic, rigid, and bedridden. In some
patients, there are also psychiatric symptoms, including schizophrenia, mood disorders,
and cognitive difficulties (Ho et al., 2001; Naarding et al., 2001). These data indicate
that mutant Htt cause multiple neurophysiological disturbances.
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Neurodegeneration in HD
The selective neurodegeneration see in HD affects mostly the corpus striatum
(Vonsattel et al., 1985). The corpus striatum consists of 3 regions of the brain, the
caudate nucleus, the putamen, and the globus pallidus (Vonsattel et al., 1985). The
neuropathology of HD is distinctive, highlighted by selective loss of striatal neurons,
mostly in the caudate and putamen (Vonsattel et al., 1985). The loss of these neurons
results in atrophy of the striatum. Other regions of the basal ganglia, such as the
substantia nigra (SN), are reduced in size due to loss of striatal projections. Neurons
from the striatum project processes into other parts of the brain including the SN, to
regulate signals from the SN. Loss of these projections results in loss of SN volume.
Some cortical and cerebellar atrophy have also been reported (Vonsattel et al., 1985).
The majority of neurons lost in HD are medium spiny neurons, which are gamma -amino
butyric acid (GABA) and glutamatergic neurons. The NADPH (nictotinamide adenine
dinucleotide phosphate) diaphorase neurons are relatively spared. Upon autopsy, HD
can be classified pathologically in Grades 0-4, based upon the severity of caudate
atrophy (Vonsattel et al., 1985). Grade 0 brains have no appreciable neuron loss,
whereas Grade 3 or Grade 4 brains have pronounced atrophy and neuron loss and
exhibit increased astrogliosis, or increased growth of reactive astrocytes. The
classification of neuropathology generally correlates with progression of the disease.
However, some Grade 0 patients exhibit clinical symptoms of HD (Vonsattel et al.,
1985). This suggests that HD symptoms occur previous to, or occur independently of,
widespread neural death. This could suggest that neurons may be dysfunctional before
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they die, and that loss of neurons is a byproduct of the disease, and not the cause of
the disease phenotype.
Htt associates with itself as well as with other proteins, forming intracellular
aggregates (IA’s). IA’s have been observed in cell nuclei and cytoplasm of postmortem
human HD brains (Becher et al., 1998; Turmaine et al., 2000). Amino (N-) terminal
fragments of expanded htt have been observed to aggregate in the nuclei and axons of
post-mortem HD brain (DiFiglia et al., 1997). In fact, only N-terminal fragments of htt
have been observed in both nuclear and cytoplasmic IA’s (Cummings et al., 2000).
Protein aggregates are much more common in dendrites than in the nucleus, and are
more common in the cortex than in the striatum in HD brain (Gutekunst et al., 1999).
These observations have been corroborated by studies in mice transgenic for full length
human htt or N-terminal fragments of htt (Hodgson et al., 1999; Mangiarini et al., 1996)
as well as in cell lines transfected with htt constructs (Cooper et al., 1998; Steffan et al.,
2000; Wang et al., 1999). Studies incorporating polyglutamine fused to Green
Fluorescent Protein (GFP) have also shown that pathological lengths of polyglutamine
are sufficient to induce aggregate formation (Ding et al., 2002; Moulder et al., 1999).
These data have been corroborated in HD “knock-in” models where the full length
mutant huntingtin is under the control of the native htt promoter (Li et al., 2001). In these
mice, aggregates in the axons of primary striatal neurons transfected with N-terminal
fragment of htt were found to inhibit axonal transport. This inhibition took place prior to
neural death, suggesting that aggregates inhibit neuronal function, which may
eventually lead to death. In several models of polyglutamine disease, IA’s have been
found to contain several different proteins. These include ubiquitin , transcription factors
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such as CREB (cyclic AMP response element binding protein) Binding Protein (CBP)
(Nucifora et al., 2001; Steffan et al., 2000) and p53 (Suhr et al., 2001) , as well as a
p53 regulator, Mouse Double-Minute-Protein 2 (Mdm2) (Suhr et al., 2001).
The contribution of aggregates to neurotoxicity is unclear. One possibility is
that the nuclear aggregates are the toxic component of HD. This hypothesis is
attractive in that transcription factors have been found in protein aggregates (Li et al.,
2002; Nucifora et al., 2001; Suhr et al., 2001; Yu et al., 2002), and dysregulation of
CBP mediated transcription has been found in mouse and cellular models of HD
(Igarashi et al., 2003; Wyttenbach et al., 2001). CBP binds to CREB, which binds to
the cyclic AMP response element (CRE) and mediates many pathways necessary for
neuronal homeostasis (Freeland et al., 2001; Jin et al., 2001). Disruption of CREB
signaling has been shown to lead to striatal neurodegeneration reminiscent of HD
(Mantamadiotis et al., 2002) . Taken together, these data indicate that loss of
transcription plays direct role in HD associated neurodegeneration. Some of the genes
mediated by CBP include genes involved in growth signaling, such as retinoid receptor
genes, and alterations in these pathways could be responsible for neuritic dystrophy
observed in both mouse and human HD. Some studies have suggested that CBP,
which also contains a polyglutamine repeat domain, is sequestered by protein
aggregates, and that this depletes available nuclear CBP in HD and other polyglutamine
disorders (McCampbell et al., 2000; Nucifora et al., 2001). However, other studies
have found that CBP as well as other transcription factors , such as SP1 (Li et al.,
2002), bind to soluble htt, and that CBP is not depleted by htt aggregates (Yu et al.,
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2002). Alternatively, aggregates in the neurites may be toxic. They could interfere with
intracellular transport, such as in the model described above (Li et al., 2001).

Oxidative Stress in HD
Oxidative stress has been implicated in the neural dysfunction and death
observed in neurodegenerative conditions such as Alzheimer’s disease (AD) (Butterfield
et al., 2002; Butterfield et al., 2002; Markesbery, 1997), Parkinson’s disease (PD)
(Blum et al., 1997), as well as HD (Browne et al., 1999). Oxidative stress has also been
observed to be a major component of neural dysfunction and death following ischemic
stroke and traumatic brain injury (TBI) (Kaya et al., 1999; Martin et al., 2003; Mattson
et al., 2001). Cells normally produce free radicals as byproducts of aerobic respiration
and other metabolic processes (Grunewald et al., 1999). These free radicals include
reactive oxygen species (ROS). ROS are highly reactive oxidants and can have
deleterious effects on cellular lipids, proteins, and DNA (Heales et al., 2002). Cells
normally have enzymes and coenzymes that act as antioxidants (Keller et al., 1998;
Reiter et al., 2002). These are able to “neutralize” ROS and prevent them from causing
damage (Heales et al., 2002). Oxidative stress occurs when the cell can no longer
mitigate the effects of ROS, resulting in pathology that can include oxidized DNA, lipids,
and proteins (Atlante et al., 2001; Mecocci et al., 1999) . ROS include the superoxide
anion (O2-) , hydrogen peroxide (H2O2), nitric oxide (NO), and hydroxyl radical (HO·)
(Keller et al., 2001). The primary site of the production of these free radicals is the
mitochondrion (Fleury et al., 2002). Superoxide is produced within the mitochondrion at
complexes I, II, III, and IV of the electron transport chain (Klein et al., 2003). A single
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electron is transferred from the electron transport chain at these sites to molecular
oxygen. The reaction of superoxide with H+ catalyzed by superoxide dismutase (SOD)
produces H2O2 (Keller et al., 2001; Klein et al., 2003). H2O2 reacts with the transition
metals Cu+ or Fe2+ via the Fenton reaction to produce the hydroxyl radical . NO is
produced by nitric oxide synthase (NOS), which catalyzes the conversion of arginine to
citrulline and NO (Deckel, 2001). NO can react with superoxide to produce the
peroxynitrite free radical (Deckel et al., 2001).
The effects of ROS on neuronal homeostasis have been extensively studied
(Browne et al., 1999; Jenner, 2003; Markesbery, 1997). ROS generation can result
from excitotoxicity, perturbances in calcium homeostasis, or disruptions to oxygen and
glucose levels during ischemia (e.g. stroke). Elevations in intracellular calcium, such as
that observed in glutamate excitotoxicity, can depolarize the mitochondrial membrane,
resulting in the release of cytochrome C, which can lead to neural death (Mattson et al.,
2001). Oxidative stress can also lead to DNA damage, which can lead to neural death.
One marker of this DNA damage is the modified nucleotide 8-hydroxy-2deoxyguanosine (8-OHdG), which has been shown to be produced by peroxynitrite
(Markesbery, 1997).
It has been hypothesized that oxidative stress mediates neuronal dysfunction
or death in HD. For example, DNA damage was detected in the form of 8-OHdG in a
mouse model of HD (Bogdanov et al., 2001). Oxidative damage to mitochondrial DNA
has also been observed in human HD (Polidori et al., 1999). Increased lipid
peroxidation has been observed in striatum of HD transgenic mice (Perez-Severiano et
al., 2000), and is correlated with a decrease in superoxide dismutase (SOD) activity and
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increased NOS activity (Perez-Severiano et al., 2002). Decreased SOD activity would
decrease H2O2 produced from excess superoxide. Increased superoxide production in
concert with increased NOS activity, would result in increased peroxynitrite levels. In a
chemical model of HD, treatment of rats with 3-nitropropionic acid, a complex II inhibitor,
leads to striatal lesions, comparable to what is observed in HD (Brouillet et al., 1999).
In these models, there is increased oxidative damage to DNA, membrane lipids, and
proteins (Browne et al., 1999). Recent studies have demonstrated antioxidants promote
neuroprotection, increased performance, and increased survival in animal models of HD
(Feigin et al., 2002). For example, treatment with the antioxidants coenzyme Q10 and
remacemide improved survival and motor performance in mouse models of HD
(Ferrante et al., 2002). Additionally, an increase in brain weight attributable to
decreased ventricle size was observed after treatment of mice with these compounds
(Ferrante et al., 2002). Lipoic acid, a compound that naturally occurs in mitochondria,
has been shown to attenuate oxidative damage, was also shown to increase mean
survival in two mouse models of HD (Andreassen et al., 2001). Taken together, these
data indicate a role for oxidative stress in mediating HD. and this may be alleviated by
antioxidant therapy.

p53 in HD
The protein p53 has been implicated in a wide array of neurodegenerative
disease and neural death due to injury (Blum et al., 1997; de la Monte et al., 1998;
Duan et al., 2002; Kaya et al., 1999). It is a pleiotropic protein with many functional
roles in the cell (Bargonetti et al., 2002). Originally, p53 was identified as an oncogene,
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but is actually a tumor suppressor (Lane et al., 1979). It was detected as a host protein
that co-precipitated with the large T antigen of SV40 when cells were transformed with
that virus (Lane et al., 1979) . Additionally, this protein was immunoprecipitated with
large T antigen in uninfected cells (Crawford et al., 1981; DeLeo et al., 1979). After
twenty plus years, it has been found that p53 mutations are present in more than half of
human cancers (Oren et al., 1999). Acting as a sequence specific transcription factor,
p53 activates genes involved in cell differentiation (el-Deiry, 1998; Maacke et al., 1997),
apoptosis (el-Deiry, 1998), and the cell cycle (Flatt et al., 2000; Winters, 2002). Cell
cycle checkpoints that are activated in response to genomic damage or other stresses
are mediated by p53. For example, the transcription of p21WAF1/CIP, a protein that
induces a G1 cell cycle arrest in response to DNA damage or other stresses, is
mediated by p53 (Balint et al., 2001; el-Deiry, 1998). The pro-apoptotic gene BAX is up
regulated by p53 (Morrison et al., 2000) and is involved in release of Cytochrome C
from the mitochondrion (Scorrano et al., 2003). Apoptosis protease activating factor-1
(APAF-1), another transcriptional target of p53, is activated by Cytochrome C and
promotes neuronal apoptosis through activation of a caspase cascade (Fortin et al.,
2001). Transcription of pro-apoptotic genes is mediated by p53 in response to
excitotoxicity, trophic factor deprivation, or hypoxia, as well as in neurodevelopment
(Miller et al., 2000; Morrison et al., 2000; van Lookeren Campagne et al., 1998) . Not
only does p53 induce pro-apoptotic genes, it also represses the promoters of genes that
respond to growth signals (Fortin et al., 2001). An array of promoters involved in
promoting cell growth, including interkeukins 2, 4, and 6 as well as the insulin promoter,
are repressed by p53.
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As a transcription factor, p53 is regulated by post-translational modifications.
Examples of these modifications include phosphorylation and acetylation (Gu et al.,
1997; Ito et al., 2001; Vousden, 2002; Woods et al., 2001). These modifications are
associated with changes in p53 activity (Ito et al., 2001), localization (Liang et al., 2001),
and/or stability. There are several regulatory domains in p53, including an N-terminal
transactivation domain, a nuclear localization sequence (NLS), nuclear export
sequences (NES), an oligomerization domain, a sequence specific DNA binding
domain, and a C-terminal regulatory domain (Balint et al., 2001; Woods et al., 2001).
Modification or interference with these domains, either through post-translational
modification or protein interaction, can greatly alter p53 stability, localization, and
activity (Ashcroft et al., 1999; Gu et al., 1997; McLure et al., 1998). Because of its role
in cell death and the cell cycle, p53 stability is tightly regulated. The half-life of p53 is
normally about 15 minutes. Under normal conditions, p53 is bound by Mdm2 (AlarconVargas et al., 2002). Mdm2 is an E3 ubiquitin ligase and targets p53 for proteolysis
(Michael et al., 2003). Mdm2 may also sequester p53 away from the nucleus
(Freedman et al., 1998). Mdm2 transcription is mediated by p53, which results in a
negative autoregulatory loop (Barak et al., 1993; Oren, 2003; Vousden, 2002).
However, in response to certain signals, such as DNA damage, p53 is phosphorylated
on residues located within the region of Mdm2 association (Gao et al., 1999; Shieh et
al., 1999). This has been suggested to attenuate the Mdm2-p53 interaction, resulting in
reduced p53 proteolysis (Ashcroft et al., 1999; Shieh et al., 1999).
Acetylation occurs on several lysine residues of p53 (Gu et al., 1997; Vousden,
2002).

The proteins that acetylate p53 are the histone acetyltransferases, or HAT
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proteins (Prives et al., 2001). These include CREB Binding Protein (CBP), p300, and
p300/CBP associated factor (P/CAF), which can also form complexes with p53
upstream of target genes (Grossman, 2001). The effect of p53 acetylation is unclear.
Earlier data suggested that p53 DNA binding activity was increased as a direct result of
acetylation (Gu et al., 1997). Recently though, it has been reported that p53 acetylation
activates transcription through the recruitment of other coactivators or transcription
factors (Barlev et al., 2001). Over expression of histone deacetylase proteins has been
shown to attenuate p53 transcriptional activity, which would be consistent with both
models (Juan et al., 2000). These observations are important for HD because
treatment of animal models of HD with histone deacetylase (HDAC) inhibitors have
been shown to ameliorate the polyglutamine-dependent neurodegeneration observed in
these animals (Steffan et al., 2001). Additionally, in a cell model of SBMA, a disease
caused by polyglutamine expansion within the androgen receptor gene (Zoghbi et al.,
2000), polyglutamine dependent cell death was attenuated by CBP over expression
(McCampbell et al., 2000). These studies were aimed at studying the role of CBP in
polyglutamine disease in the context of CBP sequestration in protein aggregates.
However, due to the effects of acetylation on p53 activity or stability, it is reasonable to
ask whether HDAC inhibition might also affect p53 activity in models of polyglutamine
disease and what effect on neurotoxicity such alterations might have.
The role of p53 in neuronal apoptosis has been studied extensively (Mattson
et al., 2001). Characteristics of apoptosis include caspase activation, chromatin
condensation and fragmentation, membrane blebbing, loss of cellular volume, and
eventual phagocytosis (Zimmermann et al., 2001). Neural death mediated by p53 has
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been implicated in a variety of disease and injury models including AD (de la Monte et
al., 1997), PD (Blum et al., 1997; Duan et al., 2002), amyotrophic lateral sclerosis
(ALS) (de la Monte et al., 1998), ischemia (van Lookeren Campagne et al., 1998),
excitotoxic injury (Culmsee et al., 2001; Uberti et al., 1998; Uberti et al., 2000), and
traumatic brain injury (Kaya et al., 1999; Napieralski et al., 1999). Studies have
suggested that neural apoptosis may be dependent on p53 transactivation of a variety
of genes. Some studies have used pharmacological inhibitors of p53, such as pifithrinα, which blocks p53 transcriptional activity (Culmsee et al., 2001; Duan et al., 2002).
Some of the genes implicated in p53 dependent neural apoptosis in both injury and
disease models include APAF-1 (Fortin et al., 2001), BAX (Blum et al., 1997; Duan et
al., 2002; Zhang et al., 2002), which code for proteins that have been implicated in
oxidative stress mediated neurotoxicity.
The role of p53 in polyglutamine neurotoxicity has not been extensively studied.
Several proteins were reported to aggregate with mutant Htt in intracellular inclusions
including p53, Mdm2, CBP, and ubiquitin (Suhr et al., 2001). Thompson and
colleagues (Steffan et al., 2000) also examined the relationship between Htt and p53 in
non-neuronal cell lines that expressed htt. The proline rich region adjacent to the
polyglutamine region of htt has been suspected to be involved in polyglutamine
neurotoxicity (Steffan et al., 2000). Htt constructs were made with and without the
proline rich region (Steffan et al., 2000). It was observed that htt and p53 coaggregate
in intracellular inclusions irrespective of the proline rich region (Steffan et al., 2000).
Glutathione-S-transferase (GST) pulldown experiments utilizing GST-Htt fusion proteins
demonstrated a direct interaction in vitro between mutant Htt and p53 that was
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dependent on the proline rich region of htt. However, this dependence was not
observed in similar studies conducted in cell culture. Additionally, p53 mediated
transcription, e.g. that of p21WAF/CIP, was repressed in cells transiently transfected with a
polyglutamine expanded htt construct. CBP and was also observed to be in intracellular
inclusions in this study. The authors proposed a model whereby p53 mediated
transcription was repressed due to the sequestration of CBP and other p53 coactivators
by the inclusions. Together these data indicate direct interaction between mutant Htt
and p53 and that p53 mediated transcription may be altered in HD.
Another study utilized cell lines derived from striatum of wild type or HD mice
(Trettel et al., 2000). The HD mice were knock in mice were polyglutamine expanded
htt was substituted for the wild type gene. Cell lines were immortalized using a
temperature sensitive large T antigen from SV40 virus. One of the observations made
was that cells from HD mice had a longer doubling time. Fluorescence Assisted Cell
Sorting (FACS) analysis revealed that there was twice the DNA content in these cells,
indicating blockage of the p53/SV40 large T antigen establishment pathway. At
restrictive temperature, there was 2 fold greater large T antigen in the mutant Htt cells
but 6 fold greater p53 expression compared to wild type cells, suggesting that
polyglutamine expansion had a role in cellular stress that stabilized or induced p53.
These data are important for HD because these studies were conducted in striatal
neurons, which are the neurons most affected in HD, and demonstrated elevated p53.
Another study was conducted in inducible mouse neural cell lines stably
transfected with either an expanded N-terminal htt fragment (60Q and150Q) or
nonpathological N–terminal htt fragment (16Q) (Jana et al., 2001). Analysis of protein
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expression revealed more p53 in the 150Q cell line than the 16Q cell line, that was
dependent on polyglutamine expansion mediated deficits in protein degradation. This
increase was concomitant with increased levels of cytosolic cytochrome C, and cell
death, suggesting a role for p53 in polyglutamine expansion mediated neural death.
One of the hallmarks of polyglutamine expansion disease is the loss of dendritic
spines from affected neurons. Loss of dendritic spines results in a decrease in neural
networking and is thought to contribute to neural dysfunction. For example, in a mouse
model of SCA1, a polyglutamine expansion disease caused by expansion in the ataxin1 protein (Zoghbi, 1995), Purkinje cells show a decrease in the number of dendritic
spines (Shahbazian et al., 2001). This may be analogous to abnormal neurite
development observed in differentiated cells expressing polyglutamine expansion (Li et
al., 1999; Song et al., 2002; Wyttenbach et al., 2001). SCA1 mice that did not express
p53 were found to have less neuropathology than SCA1 littermates that express p53
(Shahbazian et al., 2001). These mice were heterozygous for the SCA1 mutation and
homozygous for p53 deletion.

SCA1 mice that are homozygous for p53 deletion had

no difference in cell number or in early motor performance. There was no difference in
p53 expression between wildtype and SCA1 mice. These data indicate that p53 has a
role in SCA1 other than mediating cell death, perhaps by suppressing pathways that
mediate neurite outgrowth.
DNA damage and oxidative stress increase p53 expression and activity
(Geller et al., 2001) . Because both of these occur in HD (Bogdanov et al., 2001;
Deckel et al., 2002; Feigin et al., 2002), it is likely they play a role in increased p53
expression. Taken together, these studies suggest that p53 is at least stabilized, if not

14

induced, in the presence of polyglutamine expansion. Additionally, p53 has been
implicated in various models of neuronal injury and death. While the data in
polyglutamine disorders indicate that p53 is stabilized, the role of p53 in the disease
process is not clear. It may be made more active through other means than induction,
such as modifications that make p53 more stable. The role of p53 in oxidative stress
has not been fully elucidated, especially with regard to HD. Mitochondrial dysfunction
has been implicated in HD and mutant Htt has been reported to directly interact with the
mitochondrial membrane (Grunewald et al., 1999; Panov et al., 2002; Panov et al.,
2003). Oxidative stress has been associated with p53 in neurons, and it is thought that
neuron loss seen in HD may be partially mediated by oxidative stress. So it would be of
interest to study p53 in context of oxidative stress and HD, and see if a role for p53 in
these processes can be determined.
Neural death in HD is clearly caused by polyglutamine expansion in htt and is
likely mediated in part by oxidative stress. My dissertation describes research that
investigated two hypotheses. First, polyglutamine expansion and oxidative stress
induce alterations in p53 expression, stability, and activity. Second, p53 plays a direct
role in mediating oxidative stress toxicity, which is relevant to HD. Experiments
investigating polyglutamine expansion mediated alterations to p53 are described in
Chapter 2, and experiments investigating the role of p53 in oxidative stress are
described in Chapter 3. The results of these experiments and how these data fit into
what is known about HD, oxidative stress, and p53 are discussed in Chapter 4.
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Chapter Two
Polyglutamine induced changes to p53 expression, localization, and
transcriptional activity

Previous studies have suggested that p53 may have a role in polyglutamine
disorders (Jana et al., 2001; Shahbazian et al., 2001; Steffan et al., 2000; Trettel et
al., 2000). Mutant Htt has been shown to interact with p53 in one model of HD (Steffan
et al., 2000) and the absence of p53 reduces the neuropathology seen in an SCA1
mouse model (Shahbazian et al., 2001). In this chapter, I describe research that
investigated the hypothesis that polyglutamine expansion alters p53 expression,
stability, and activity.
I utilized SH-SY5Y cells, a human neural cell line, that stably express a fusion of
Green Fluorescent Protein (GFP) and either physiological or pathological lengths of
polyglutamine (19-GFP and 56-GFP, respectively) (Ding et al., 2002). The expression
of p53 mRNA and p53 protein was analyzed, and p53 stability assessed in these cells.
The intracellular localization of p53 was visualized using immunocytochemical
techniques. Additionally, post-translational modifications of p53 were noted,
specifically, acetylation and phosphorylation. The possible involvement of Mdm2, a key
protein in p53 biology, was also investigated. Mdm2 expression and localization were
determined in 19-GFP and 56-GFP cells, and its interaction with p53 in these cells
analyzed. In order to determine how p53 is altered in vivo, I conducted additional
experiments. In these studies, I analyzed p53 expression in human HD brains as well
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as in an HD mouse model. To determine modifications to p53 in vivo, I examined
mouse and human brains for acetylated and phosphorylated p53.

p53 expression and stability
The expression of p53 was examined in SY5Y cells that stably express 19-GFP
or 56-GFP (Figure 1). SY5Y cells express wild type p53, unlike many other tumor
derived cell lines (Rodriguez-Lopez et al., 2001). SY5Y cells utilized in this study were
either undifferentiated or differentiated. These cells can be differentiated with retinoic

Figure 1. Expression of p53 is altered in neural cells expressing polyglutamine
expansion. The expression of p53 protein was examined by Western blot analysis
in undifferentiated (A) or retinoic acid differentiated (B) 19-GFP and 56-GFP
expressing neural cells. p53 mRNA expression of duplicate samples was examined
by RT-PCR in undifferentiated (C) or differentiated (D) 19-GFP and 56-GFP cells.
p53 mRNA expression was normalized to that of 18s rRNA. Data shown are
representative of results from 3 similar experiments.
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acid. This induces a G1 cell cycle arrest and development of a neural phenotype
(Tucholski et al., 2001) . Undifferentiated 56-GFP expressing cells had approximately
120% more p53 protein expression than 19-GFP cells (Figure 1A). Differentiated 56GFP cells had about 20 % more p53 protein expression than differentiated 19-GFP cells
(Figure 1B). This data is not quantitative because there was no analysis conducted for
loading. For example, the expression of actin or some other “housekeeping” protein
could have been analyzed to control for loading. However, I conducted these
experiments several times, and the increase in p53 expression was always observed in
56-GFP cells compared to 19-GFP cells. In differentiated 19-GFP and 56-GFP
expressing cells, p53 mRNA expression was similar (Figure 1D). However, p53 mRNA
was elevated in undifferentiated 56-GFP cells compared to undifferentiated 19-GFP
expressing cells (Figure 1C). Because neurons are in a post-mitotic state in the brain, I
decided to conduct subsequent experiments with terminally differentiated cells, except
where noted.
The level of p53 protein in the cell can be increased, or stabilized by either
transcriptional activation of the p53 gene, or stabilization of the p53 protein (AlarconVargas et al., 2002; Ashcroft et al., 1999). Since p53 mRNA was not increased in
differentiated 56-GFP cells, compared to 19-GFP cells, experiments were conducted to
determine if p53 protein was stabilized in these cells. Differentiated 19-GFP and 56GFP expressing SY5Y cells, as well as differentiated wild type SY5Y cells, were
incubated with cycloheximide (Figure 2).
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A.
Minutes

p53

B.

Figure 2. p53 expression is altered in neural cells that express polyglutamine
expansion. Differentiated 19-GFP and 56-GFP cells were treated with 10 µM
cycloheximide. Following treatment, the cells were collected at the times indicated
(minutes, A) and p53 expression examined in 50 µg total protein by Western blot
analysis (A). Note the multiple bands observed for 56-GFP cells (arrow, A). Bands
were examined by dose densitometry and the percent control (0 minutes) of p53
expression for 19-GFP and 56-GFP calculated (B). The blot (A) and graph (B) are
representative of 2 experiments.
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Cycloheximide inhibits the translocase step of translation (Obrig et al., 1971), thereby
halting the synthesis of new protein. Lysates of 19-GFP and 56-GFP cells collected at
various times after treatment with cycloheximide were analyzed for p53 protein
expression. The level of p53 decreased faster in 19-GFP (Figure 2A, left panel)
expressing SY5Y cells than in 56-GFP cells (Figure 2A, right panel). Levels of p53
expression in both 19-GFP and 56-GFP cells were quantified by densitometry and
plotted as percent control for each cell line (Figure 2B). At 60 minutes post-treatment,
in 56-GFP cells there was 68% of the p53 level observed in control. However, in 19GFP cells after 60 minutes cycloheximide treatment, there was 38 % of p53 observed
in control cells. These data suggest that polyglutamine expansion somehow stabilizes
p53 protein, and that this accounts the increased preservation of p53. In 56-GFP cells,
a triple band was observed (arrow, Figure 2A). The lower bands are consistent with
p53 that has been phosphorylated. Phosphorylation of p53 causes an electrophoretic
shift, and data supplied by the manufacturer of an antibody to phosphorylated p53 that I
used reported that phosphorylated p53 runs at 47kD. It was also noted that with
increasing time after cycloheximide treatment, there appeared to be a redistribution of
p53 amongst the different bands (Figure 2B). Specifically, the lowest band increased in
intensity and the upper bands decreased in intensity. This could indicate that with
increasing time following cycloheximide treatment, stable p53 is modified.
Phosphorylation of p53 has been associated with increased stability of the protein, so
this could explain the redistribution observed in Figure 2A (Shieh et al., 1997).
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One protein that has a role in the normal turnover of p53 is Mdm2 (AlarconVargas et al., 2002; Ashcroft et al., 1999; Kubbutat et al., 1998). Mdm2 functions as
an E3 ubiquitin ligase and is known to mediate the proteolysis of p53. Given that p53 is
stabilized in 56-GFP expressing cells compared to 19-GFP cells or wildtype, I
conducted experiments to determine if Mdm2 plays a role in p53 stability. Mdm2
expression was increased in 56-GFP cells compared to
19-GFP cells (Figure 3). Increased Mdm2 typically leads to increased turnover of p53
kD

19-GFP

56-GFP

125
Mdm2
81

39
Figure 3. Mdm2 expression is altered in neural cells expressing
polyglutamine expansion. Mdm2 expression was analyzed in a total of 50 µg
protein from differentiated 19-GFP or 56-GFP cells. Blot is representat i
of 2 similar experiments.
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(Freedman et al., 1998; Kobet et al., 2000; Kubbutat et al., 1998). These data taken
together with the data in Figure 2 suggest that p53 is stabilized in 56-GFP expressing
cells in the presence of increased levels of MDM2 compared to 19-GFP expressing
cells.
Nuclear localization is required for p53 transcriptional activity (Vousden, 2002).
Additionally, Mdm2 localization in the nucleus has a role in p53 stability (Freedman et
al., 1998; Kobet et al., 2000; Kubbutat et al., 1998) . Because of these factors, I next
analyzed the localization of p53 in human neural cells expressing 19-GFP or 56-GFP.
In 19-GFP expressing cells, p53 was barely detectable, and localized throughout the
cell (Figure 4A). In 56-GFP, there was much higher p53 expression, but p53 was
chiefly localized to the nucleus (Figure 4B). The majority of Mdm2 was localized to the
nucleus as well in 19-GFP cells (Figure 4C). There was consistently more p53
immunoreactivity in 56-GFP cells compared to 19-GFP cells. In 56-GFP cells, p53 was
predominantly localized to the nucleus (Figure 4D). These data, taken with the data in
Figure 3, suggest that p53 coexists with increased levels of Mdm2, even though Mdm2
normally mediates the degradation of p53.
To investigate the p53-Mdm2 interaction in 19-GFP and 56-GFP cells, I
conducted immunoprecipitation (IP) experiments (Figure 5). In 19-GFP cells, there was
more interaction between p53 and Mdm2 than in 56-GFP cells. Specifically, the
intensity of the band representing Mdm2 that was precipitated with p53 antibody in 56GFP cells was 3.8% of the total Mdm2 protein in 56-GFP cells. Mdm2 protein
precipitated in 19-GFP cells was 7.9% of the total Mdm2 in 56-GFP cells. A comparison
of Mdm2 precipitated in 19-GFP cells to total Mdm2 protein in 19-GFP cells was not
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p53

Mdm2

Figure 4. Polyglutamine expansion alters expression of p53 and Mdm2 in
human neural cells. The expression of p53 (A, B) and Mdm2 (C,D) were
analyzed by immunocytochemistry in undifferentiated 19-GFP (A,C) and 56-GFP
(C,D) expressing SY5Y cells under basal conditions. Images are representative
of results from at least 3 similar experiments. Total magnification was 400X.

made. Another measurement that would have been useful but was not conducted
would be to determine the ratio of Mdm2 protein precipitated by p53 antibody to p53
protein precipitated by the same antibody. These measurements would have helped
determine the fraction of Mdm2 interacting with p53 in 19-GFP and 56-GFP cells.
Taken together, these data suggest that there is more Mdm2 expressed in 56-GFP
cells, but there is also less interaction between Mdm2 and p53 in 56-GFP cells
compared to 19-GFP cells. Less interaction between p53 and Mdm2 could indicate that
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there is less Mdm2 mediated proteolysis of p53 in 56-GFP cells. This would be
consistent with the data that indicated that p53 was more stable in 56-GFP cells than in
19-GFP cells (Figure 2). To evaluate the role of Mdm2 in polyglutamine toxicity, I
utilized antisense oligonucleotides to reduce Mdm2 expression in 19-GFP and 56-GFP
cells (Figure 6A). Treatment of 56-GFP cells with antisense oligonucleotide reduced
Mdm2 protein expression by approximately 40% (Figure 6A). Treatment of cells with a
scrambled oligonucleotide had no effect on Mdm2 expression (Figure 6A). Inhibition of

kD

MW

19-GFP

56-GFP

Non-IP

124
Mdm2

101

55

Figure 5. The interaction of p53 with Mdm2 is altered in polyglutamine
expansion expressing cells. Lysates from 19-GFP and 56-GFP expressing cells
(200 µg total protein) were incubated with p53 antibody and precipitated with
Protein G coated sepharose beads. Precipitated proteins were analyzed by
Western blot to determine Mdm2 level. Molecular weight markers (MW) were
used to identify Mdm2. To demonstrate normal expression of Mdm2, a total of 50
µg protein from 56-GFP lysate (Non-IP) was also analyzed. Blot is representative
of 2 experiments.
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Mdm2 expression resulted in neural death in both differentiated and
undifferentiated cells (Figure 6B, C), although the cell death was much greater in 56GFP cells compared to 19-GFP cells. It did not appear that differentiation had an effect
on sensitivity of antisense (Figure 6B, C), as 56-GFP cells with or without retinoic acid
differentiation had similar amounts of death. This was also observed in 19-GFP cells
(Figure 6B, C). Taken together, these data suggest that decreased Mdm2 is toxic for
both 19-GFP and 56-GFP cells, but, much more toxic for 56-GFP cells. Taken together
with the earlier data, this would suggest that Mdm2 plays a role in mitigating
polyglutamine expansion toxicity.

p53 is modified in neural cells expressing polyglutamine expansion
Previous studies have suggested that post-translational modifications of p53 alter
its interactions with other proteins, particularly Mdm2 (Ashcroft et al., 1999). Two of
these modifications are phosphorylation and acetylation (Gu et al., 1997). Additionally,
phosphorylation and acetylation of p53 have been suggested to alter p53 transcriptional
activity (Gao et al., 1999; Gu et al., 1997; Shieh et al., 1997). To determine whether
p53 was differentially acetylated or phosphorylated in the presence of polyglutamine
expansion, lysates from 19-GFP and 56-GFP expressing cells were examined by
Western blot analysis using antibodies that recognize either acetylated or
phosphorylated p53. Acetylation of p53 on Lysine 320 was observed in 56-GFP cells
(Figure 7A), but little or no acetylated p53 was observed in 19-GFP cells (Figure 7A).
Phosphorylation of p53 on Serine 15 was also detected in 56-GFP cells, with little or
none detected in 19-GFP cells (Figure 7B). However, there was also less p53 in 19-
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GFP cells compared to 56-GFP cells (Figure 1). This could account for the decreased
modified p53 observed in 19-GFP cells.

Genetic Inhibition of p53 activity attenuates polyglutamine neurotoxicity
To address whether polyglutamine expansion mediated changes to p53 activity
alter neural homeostasis, I utilized another neural cell line (PC12) that stably expresses
a p53 temperature sensitive mutant (ts p53 cells) that is deficient in DNA binding
(Hughes et al., 2000). Mutant p53 is overexpressed at the restrictive temperature
(39oC). PC12 cells expressing ts p53 were transiently transfected with 56-GFP DNA
(Ding et al., 2002). As a control, cells that stably expressed only empty retrovector

81 kD

Acetylated p53

55 kD

Phosphorylated
p53

Figure 7. p53 is modified in cells expressing polyglutamine expansion. Lysates
from differentiated 19-GFP and 56-GFP cells were analyzed by Western blot for
expression of acetylated (A) and phosphorylated (B) p53. Acetylated p53 was
detected with an antibody that recognizes p53 acetylated on lysine 320.
Phosphorylated p53 was detected with an antibody that recognizes only p53
phosphorylated on serine 15. Blots are representative of results from at least 3
similar experiments.
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With 56-GFP
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Figure 8. p53 DNA binding activity is required for polyglutamine
expansion induced neural death. PC12 neural cells were stably transfected with
either empty retrovector (vector cells, A-C) or a p53 temperature sensitive (ts p53)
mutant deficient in DNA binding (ts cells, D-E). Both cell lines were transiently
transfected with plasmid DNA encoding 56-GFP. After incubation at the restrictive
temperature for 48 hours, cell morphology and death were examined. PC12 cells
were visualized under phase contrast optics (A,D). Cell nuclei were visualized using
Hoescht 33344, a dye that binds DNA. Expression of 56-GFP was visualized using
fluorescence optics (C,F) . Note the aggregates in vector cells cells (C, arrow).
PC12 cells, stably expressing empty retrovector (●) or ts p53 (●), were transiently
transfected with 56-GFP. Cell death was assessed by visualization of cell nuclear
morphology with Hoescht stain (G). Data represents the percentage of cells with
fragmented or condensed nuclei. Error bars represent the S.E.M. of 6 cultures. Data
shown is representative of 3 similar experiments. Error bars represent S.E.M for at
least 5 cultures. ** p < 0.001 compared to vector cells
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(vector cells) were also used. Some cultures were also mock transfected. These
cultures underwent the same transfection procedure without the addition of 56-GFP
DNA. After 48 hours of incubation at the restrictive temperature, expression of 56-GFP
was observed in both vector and ts p53 cell lines (Figure 8C and 8F). Protein
aggregates containing 56-GFP were observed in both vector (Figure 8C) and ts p53
cells (data not shown) . Diffuse expression of 56-GFP was also seen in vector cells
(data not shown) and ts p53 cells (Figure 8F). At that time, the cells were assayed for
death by visualization of their nuclei with Hoescht stain (Figure 8B and 8E). Cells were
counted as dead if they had fragmented or condensed chromatin which are
characteristics of apoptotic death (Zimmermann et al., 2001). Cells that contained the
empty vector had increased nuclear condensation and/or fragmentation following
transfection with 56-GFP DNA (Figure 8G). In contrast, cells that express the p53
mutant had much less cell death (Figure 8G). The amount of cell death seen in p53
mutant cells was comparable to that seen in cells that were mock transfected (data not
shown. Neural death was alleviated in cells over expressing ts p53. Taken together,
these data suggest a role for p53 transcriptional activity in polyglutamine neurotoxicity.

p53 in HD mice and human HD
The in vitro studies suggest that in neural cells p53 is altered in the presence of
polyglutamine expansion, and that this has implications for neural homeostasis. When
p53 is unable to bind to DNA, polyglutamine neurotoxicity is
attenuated as observed in the ts p53 expressing PC12 cells. These studies were
conducted in rodent cell lines. The constructs used were fusions of
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polyglutamine and GFP. Polyglutamine fusions with innocuous proteins have been
shown to induce characteristics similar to those seen in polyglutamine disorders (Marsh
et al., 2000; Ordway et al., 1997). However, in order to examine alterations to p53
expression in the context of HD, I sought to compare and contrast p53 expression and
modification in vivo. The expression of p53 was determined in an HD mouse model (R
6/2) as well as in human HD brain. Additionally, acetylated and phosphorylated p53
were examined in HD mice and human HD brains. R 6/2 mice are transgenic for an Nterminal fragment of human htt containing the region of polyglutamine expansion
(Mangiarini et al., 1996). These mice are pre-symptomatic before approximately 8
weeks of age, after which they develop a progressive neurological phenotype
(Mangiarini et al., 1996). These mice develop a resting tremor and seizure activity has
been observed, evidence that there are neurophysiological abnormalities. When
suspended by their tail, R6/2 mice clasp their back feet whereas a wild type mouse will
splay his limbs to steady itself. They do not exhibit the neurodegeneration specific to
the striatum as do human HD patients, but brain size is decreased approximately 20%
compared to age-matched controls. Protein aggregates reminiscent of those seen in
HD are also found in R6/2 brains (Davies et al., 1997). Late in life (17 weeks), R6/2
mice develop neurodegeneration of the cerebellum, cortex, and striatum. There is
condensation of the cytoplasm and nucleus, but no DNA fragmentation , which would be
characteristic of nucleosomal cleavage , a marker for apoptotic death (Hickey et al.,
2003; Turmaine et al., 2000).
The expression of p53 and modified p53 were examined in R6/2 mice. There
appeared to be decreased p53 expression in 4 week old HD mice compared to control
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mice (Figure 9A, left panel). There also appeared to be less p53 protein in the brains of
10 week old HD mice compared to control

(Figure 9A, right panel). There appeared to

be more phosphorylated p53 in 4 week old control mice compared to HD mice (Figure
9B, left panel). There was also more phosphorylated p53 in 10 week old control mice
than in 10 week old HD mice (Figure 9B, right panel). It was unclear if there was a
change in phosphorylated p53 with age in either control or HD mice. In pre-symptomatic
HD mice, there was slightly less acetylated p53 compared to control mice, though there
was variability from animal to animal (Figure 9C, left panel). There was no difference in
acetylated p53 levels between HD and control mice of either age (Figure 9C, right
panel), and it appears that acetylated p53 is increased with age in both HD and wild
type mice. Acetylated and phosphorylated p53 are associated with increased p53
transcriptional activity. It is unclear whether decreased level of phosphorylated p53 in
HD mice is due to reduced p53 expression in these mice, or whether reduced p53 is
due to reduced phosphorylation of p53. Taken together, these data suggest that p53
and phosphorylated p53 are more prevalent in control mice than in R6/2 mice, and that
acetylated p53 is unchanged in symptomatic HD mice compared to control. However,
expression levels were not normalized to an innocuous protein such as actin or Βtubulin to account for loading differences in each lane, so it is difficult to determine how
much difference there is for each p53 species between HD and control mice.
The expression of p53 was also examined in human HD and control brains
(Figure 10). The brains obtained from HD patients exhibited Grade 4 pathology, and
the post-mortem interval was approximately 18 hours. Brains with this pathology exhibit
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Figure 9. Expression of p53 and post-translational modifications to p53
are altered in HD mice. Lysates prepared from the cortices of either
presymptomatic (4 week) or symptomatic (10 week) HD (R 6/2) or control mice
were examined by Western blot analysis for (A) p53 (B) phosphorylated p53
and (C) acetylated p53. For (C), the blot in A was stripped and then reprobed
with acetylated p53 antibody. Data shown represent 2 animals for each
timepoint. Blot is representative of 2 experiments.
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severe loss of neurons in the caudate and pronounced astrogliosis (Vonsattel et al.,
1985). The expression of p53 protein was detected in control brain, though the level
varied from patient to patient (Figure 10A, left panel). Little or no p53 was detected in
HD brains (Figure 10A, right panel). Phosphorylated p53 was detected in control
brains, though levels varied from patient to patient (Figure 10B, left panel). Brains from
HD patients all expressed phosphorylated p53, though the level varied from patient to
patient (Figure 10B, right panel). All brains examined expressed acetylated p53, though
there was consistently less in HD patients compared to control (Figure 10C). The level
of acetylated p53 varied from patient to patient in both control and HD patients. Taken
together, these data indicate a different pattern of expression in human HD than the in
vitro studies conducted using polyglutamine-GFP constructs. With increasing
polyglutamine expansion (HD patients), there was less p53 expression compared to
control brains. These data are in contrast to in vitro studies, where more p53
expression was observed in 56-GFP expressing cells than in 19-GFP expressing cells
(Figure 1A and 1B)
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Figure 10. The expression of p53 is altered in HD Brain. Samples from
the caudate of 4 control and 4 HD human brains were examined for p53
expression. Western blot analysis was used to determine levels of p53 (A),
phosphorylated p53 (B), and acetylated p53 (C). The blot in C was stripped
and reprobed with p53 antibody to give the blot seen in A. Blots are
representative of 2 separate experiments.
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Chapter Three
Oxidative Stress Mediated Alterations to p53 Expression and Transcriptional
Activity

Oxidative stress has been implicated in HD from several lines of evidence
(Andreassen et al., 2001; Perez-Severiano et al., 2002; Polidori et al., 1999; Schilling
et al., 2001). Whether oxidative stress is a causal factor in HD, or a secondary effect of
the disease is unclear. Dysfunctions in energy metabolism and mitochondria have been
suggested to lead to oxidative stress in HD (Browne et al., 1999). Oxidative stress has
been noted in animal models of HD that express polyglutamine expansion (PerezSeveriano et al., 2000; Wyttenbach et al., 2002). Oxidative stress has also been
implicated in animals that develop HD-like neurodegeneration following treatment with
3-nitropropionic acid and quinolinic acid (Kim et al., 2002; Takahashi, 1999). The
hypothesis that oxidative stress plays a role in HD and chemical models of HD has been
strengthened by studies showing that antioxidant therapy improves survival and motor
skills in HD models (Beal, 2002; Ferrante et al., 2002).
In order to address the hypothesis that p53 expression and activity is altered
following oxidative injury, I utilized neural cells, both primary cultures and human neural
cell lines. I used primary rat embryonic neuronal cultures (embryonic day 18 or E18).
These cultures are of a mixed nature, containing several types of cells, both neuronal
and non-neuronal (Keller et al., 1998; Keller et al., 1999), and could perhaps better
represent what is happening in the brain than immortal cell lines.
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To induce oxidative stress, I treated primary cortical rat neurons with hydrogen
peroxide (H2O2) (Figure 11). Exogenous H2O2 has been used to induce oxidative stress
in a variety of cell types (Datta et al., 2002; Ouyang et al., 2002; Uberti et al., 1999),
and causes p53 dependent apoptosis in glial cells (Datta et al., 2002). Cultures were
treated with H2O2 for 24 hours and their nuclei visualized with Hoescht stain. Phase
contrast visualization of the cells revealed dystrophic neurites in treated cells, a
characteristic lacking in control cells (Figure 11A and 11C, respectively). Neurons were
counted as dead if they had condensed (Figure 11D) or fragmented (Figure 11B)
chromatin. Neurons were counted, and the percentage of dead neurons determined.
H2O2 induced a dose-dependent increase in neural death (Figure 11E). There was
some variability from experiment to experiment, but 10 µM and 50 µM concentrations
consistently yielded significant increases in neural death (Figure 11E, 13).
To determine if p53 expression is altered in primary neurons treated with H2O2,
lysates of primary neuronal cultures were examined by Western blot analysis. There
were time- and dose-related changes in p53 expression (Figure 12). In most
experiments, there was a modest increase in p53 levels, even with 1 µM H2O2 (Figure
12A, B). Dose densitometry was used to measure the intensity of relevant bands. The
percent of band density at each time point compared to control cultures (0 Hours) were
calculated and plotted with respect to time (Figure 12B). Surprisingly, even with the
more lethal doses, such as
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Figure 11. H2O2 induces dose dependent neural death. Cultured rat neurons
were treated with the indicated concentrations of H2O2 for 24 hours. Control cells
received no treatment (0 µM H2O2) (A,B). Control (A) and treated (C, 10 µM H2O2)
cells were visualized under phase contrast optics to assess cell type and morphology,
Cell death was assessed in control and treated cells by visualization of cell nuclear
morphology with Hoescht stain (B, D). Data in (E) represents the percentage of
neurons with condensed or fragmented (B,double arrow) nuclei. Error bars
represent the S.E.M. of 6 cultures. Data shown is representative of 3 similar
experiments. *p< 0.01 compared to control. ** p< 0.001 compared to 1µM H2O2. ***
p<0.05 compared to 10 µM H2O2. **** p< 0.05 compared to 25 µM H2O2
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50 µM H2O2, there was often a return to basal p53 levels or even a reduction in p53
expression after 24 hours (Figure 12B). Overall, the data revealed that there were
modest, transient increases in p53 expression in these cells, but never a very large
increase, even with the higher doses.
Although p53 expression was not greatly altered, even in the presence of H2O2
induced cell death, p53 could still be involved with cell death if p53 transcriptional
activity were increased. Transcriptional activity of p53 has been shown to be inhibited
by the compound pifithrin-α (Komarov et al., 1999). In one study, pifithrin-α inhibited
neuron loss following excitotoxic and genotoxic injury, as well as ischemic injury
(Culmsee et al., 2001).
The mechanism for p53 inactivation by pifithrin is unclear, although nuclear
accumulation of p53 is reduced by pifithrin in liver cells (Schafer et al., 2003), which
presumably prevents p53 from interacting with nuclear DNA. Neurons were treated
with H2O2 in the absence or presence of pifithrin. Pifithrin reduced the neural death
induced by H2O2 at both concentrations tested (Figure 13). Taken together, these data
suggest that oxidative stress induced by H2O2 induces dose dependent death in primary
neurons. This is mediated, at least in part, by p53 transcriptional activity, as
pharmacological inhibition of p53 attenuates neural death. It is unclear whether
upregulation of p53 is responsible for neural death induced by H2O2, as p53 levels were
not greatly changed, or an increase in p53 activity is responsible.
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Figure 12. H2O2 alters p53 expression in rat cortical neurons. Rat cortical
neurons were isolated from E18 embryos and cultured for 5-7 days. Cells were
treated with 1 µM,10 µM, or 50 µM of H2O2. At the indicated times after treatment,
cells were collected and lysed. Cell lysates of 50 µg total protein were examined for
p53 expression by Western blot analysis (A). Densities of bands corresponding to
p53 were analyzed, percent control calculated for each dose, and plotted against
length of treatment (B). (A) and (B) are representative of 3 experiments.
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Figure 13. Pharmacological inhibition of p53 attenuates neural death induced
by oxidative stress . Cultured rat neurons were treated with the indicated
concentrations of H2O2 for 24 hours in the absence (●) or presence (●) of 1 µM
pifithrin. Cell death was assessed by visualization of cell nuclear morphology with
Hoescht stain. Data represent the percentage of cells with fragmented or condensed
nuclei. Error bars represent S.E.M for at least 6 cultures. * p<0.05 compared to 10
µM H2O2. ** p < 0.001 compared to 50 µM H2O2. Graph is representative of 3 similar
experiments.

Inhibition of p53 Attenuates H2O2 Mediated Death in Neural Cells
To further investigate the role of p53 activity in oxidative stress mediated neural
death, a human neural cell line was utilized. Undifferentiated SY5Y cells were treated
with H2O2 in the absence or presence of pifithrin. After 24 hours, cell death was
analyzed by Hoechst staining. H2O2 induced a dose-dependent death (Figure 14),
which was inhibited by pifithrin at both tested concentrations. Attenuation was
incomplete, with less than a 20% decrease in neural death induced by 50 µM H2O2.
There was approximately a 40% attenuation of neural death induced by 10 µM H2O2.
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Figure 14. Pharmacological inhibition of p53 attenuates cell death
induced by oxidative stress in human neural cells. Neural SH-SY5Y cells
were treated with the indicated concentrations of H2O2 for 24 hours in the
absence (●) or presence (●) of 1 µM pifithrin. Cell death was assessed by
visualization of cell nuclear morphology with Hoescht stain. Error bars
represent the S.E.M. of at least 6 cultures. ** p < 0.002 compared to H2O2.
Graph is representative of 3 similar experiments.

Since primary neurons are post-mitotic cells, I utilized retinoic acid differentiated
SY5Y cells in similar experiments. Similar to undifferentiated SY5Y cells and primary
neurons, cell death was also attenuated by pifithrin (Figure 15). There was no
significant difference between control and 10 µM H2O2 with pifithrin, unlike in
undifferentiated cells. However, at the concentration tested, 10µM, there was
approximately half of the cell death observed in undifferentiated cells (Figure 15).
Taken together, these data indicate that H2O2 induces cell death in human neural cells
as was observed in rat primary neurons. Pharmacological inhibition of p53
transcriptional activity attenuated H2O2 induced
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Figure 15. Pharmacological inhibition of p53 activity attenuates oxidative
stress induced death of differentiated human neural cells. Differentiated
SY5Y cells were treated with 10 µM or 50 µM H2O2 in the absence (●) or
presence (●) of 1 µM pifithrin. Cell death was assessed by visualization of cell
nuclear morphology with Hoecsht stain. Data shown represent the percentage
of cells with fragmented or condensed nuclei. Error bars represent S.E.M. of 6
cultures. * p < 0.01 compared to control. ** p < 0.001 compared to 10 µM H2O2.
## p <0.001 compared to 50 µM H2O2 without absence. Graph is
representative of 2 similar experiments.

cell death. These data suggest that there is a role for p53 transcriptional activity in
oxidative injury mediated neural death.

A Genetic Inhibitor of p53 Attenuates H 2 O 2 nduced Death
A primary concern with using pharmacological inhibitors is that of specificity. To
further corroborate the data implicating p53 in oxidative stress mediated neurotoxicity, I
utilized cell lines defective in p53 DNA binding
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(Hughes et al., 2000) . At restrictive temperature (39 oC), these cells over-express
mutant p53, which effectively abrogates p53 mediated transcription. PC12 cells were
treated with H2O2 for 24 hours and their nuclei visualized with Hoescht stain (Figure 16).
PC12 cells that contained only the vector died in a dose dependent manner following
treatment with H2O2. However, cell death was almost completely blocked in cells
expressing mutant p53. To further corroborate these data, cultures treated in the same
way were analyzed for cell survival by MTT analysis. The MTT assay measures the
reduction of MTT [(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], which
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Figure 17. Genetic inhibition of p53 DNA binding attenuates neural death
induced by H2O2. PC12 cells stably transfected with either empty retrovector
(■), or a p53 mutant deficient in DNA binding (■), were treated with the
indicated concentrations of H2O2 for 24 hours. Cell survival was determined by
the MTT assay. Percent cell survival compared to untreated cells was
determined. Error bars represent S.E.M. of 8 cultures. **p < 0.001 compared
to cells containing empty retrovector. Graph is representative of at least 3
similar experiments.
produces a blue-violet color. The ability of cells to reduce MTT is a measure of cell
viability. MTT analysis of cell death indicated that neurotoxicity was attenuated greatly
in cells that express ts p53 (Figure 17). Taken together, these data indicate that p53
transcriptional activity is a factor in oxidative stress induced neurotoxicity. These data
taken with the pifithrin studies suggest a role for p53 transcriptional activity in mediating
neural death following oxidative injury.
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Chapter Four
Discussion and Conclusions

Expression and regulation of p53
The tumor suppressor protein p53 has a myriad of roles in the normal cell. For
example, p53 has roles in the cell cycle, neuronal differentiation and apoptosis. Most of
the literature on p53 has been in the context of its role in cancer. At least 50% of
human cancers are linked to mutations in p53 (Vousden, 2002). Its role in
neurodevelopment has been studied extensively as well (Miller et al., 2000). Some
studies have implicated p53 in neural trauma or neurodegenerative disease, although
its role has not been fully elucidated. The involvement of p53 in polyglutamine
disorders has been suggested but not fully studied (Shahbazian et al., 2001; Steffan et
al., 2000; Suhr et al., 2001; Trettel et al., 2000). Other transcription factors, however,
including SP1 and CBP, have been studied in polyglutamine disorders. Soluble, but not
aggregated, mutant Htt has been found to interact directly with SP1, and in doing so,
repress SP1 mediated gene transcription (Li et al., 2002) . The genes affected include
the nerve growth factor mediated pathways, which are responsible for neuritic outgrowth
responsible for retinoid signaling, important pathways for maintaining
neurohomeostasis. Loss of these pathways leads to neural dysfunction and neurite
retraction in a cell model of HD (Li et al., 2002; Wyttenbach et al., 2001). These events
are also observed in human HD. At present, it is unclear how the loss of CBP and SP1
occur in HD.
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Since p53 is a potent regulator of the cell cycle and apoptotic pathways, p53
expression and activity are tightly regulated by the cell (Alarcon-Vargas et al., 2002;
Ashcroft et al., 1999). When p53 is mutated, uncontrollable cell growth can result,
leading to cancer. If p53 is inappropriately active, then premature cell death can occur.
In my studies, increased levels of p53 were present in the nucleus in cells expressing
pathological lengths of polyglutamine (Figure 4B). When p53 is activated, or induced, it
is localized to the nucleus, and nuclear export is minimized, befitting its role as a
transcription factor (Vousden, 2002). This increase in p53 levels can be due to induction
of the p53 gene, leading to production of p53 protein, or it can be due to stabilization of
existing p53 protein. Under normal conditions, p53 concentrations are relatively low
due to its short half-life. At the transcriptional level, p53 can be induced by a variety of
insults, the best studied of which is genotoxic stress (Balint et al., 2001; Shieh et al.,
1997; Shieh et al., 1999; Shieh et al., 2000; Vousden, 2002). The activity and stability
of p53 is regulated by both post-translational modifications and interaction with other
proteins. In my studies, I found that p53 expression and activity were altered in vitro.
In chapter 2 I described research aimed at investigating the hypothesis that p53
expression and activity is altered in the presence of polyglutamine expansion. In SY5Y
neural cells, the p53 protein levels were greater in cells that expressed 56-GFP than in
19-GFP (Figure 2). Increases in p53 stabilization was not associated with increased
mRNA abundance of p53 (Figure 1D). Two pieces of evidence support this. When
protein synthesis was halted, p53 protein was observed to be more stable in 56-GFP
cells than in 19-GFP or wild type cells (Figure 2). Additionally, levels of p53 mRNA
were the same for 19-GFP and 56-GFP expressing cells (Figure 1B).
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The stability of p53 is largely mediated through p53 interaction with Mdm2
(Alarcon-Vargas et al., 2002). Mdm2 has E3 ubiquitin ligase activity and ubiquitinates
p53. This can lead to localization of p53 to the cytosol where it is degraded by the 26S
proteasome (Freedman et al., 1999). Mdm2 is transcriptionally transactivated by p53
(Barak et al., 1993), thereby participating in a p53 mediated negative autoregulatory
loop (Alarcon-Vargas et al., 2002; Ashcroft et al., 1999; Freedman et al., 1999). Mdm2
has also been found to be important for regulation of p53 activity in neuroblastoma
derived cell lines, such as the SH-SY5Y cells used in my studies (Rodriguez-Lopez et
al., 2001). In my studies, Mdm2 expression was found to be higher in 56-GFP cells than
in 19-GFP (Figures 3, 4C, 4D). Mdm2 was localized chiefly in the nucleus, as revealed
by immunocytochemistry (Figures 4C, D). Mdm2 immunoreactivity was more intense in
the nuclei of 56-GFP cells, consistent with the immunoblot data (Figures 4D and 3,
respectively). The expression of p53 was higher in 56-GFP cells and localized in the
nucleus (Figure 4A), despite the increased expression of Mdm2 (Figure 3, 4B). While
the immunoprecipitation data was not convincing on its own, there did appear to be
more interaction of Mdm2 with p53 in 19-GFP cells compared to 56-GFP cells. More
work needs to be done in the area of p53 protein-protein interaction, but it appears that
there may be differences between the two cell lines.

Taken together, these data

indicate that p53 is stabilized in the presence of increased Mdm2 levels in 56-GFP
expressing cells, and that this may involve there being less interaction between Mdm2
and p53 in 56-GFP expressing cells.
The mechanism behind this change in p53-Mdm2 interaction is unclear. Recent
studies have linked other protein interactions with either p53 or Mdm2 and p53 stability.
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For example, the HAT protein p300 has been shown to interact with both Mdm2 and
p53 (Grossman et al., 1998), and participates in Mdm2 mediated degradation of p53,
perhaps through its own ubiquitin ligase activity (Grossman et al., 2003). I did conduct
experiments investigating the interaction between Mdm2 and p300, but the results were
inconclusive (data not shown). There is no difference in viability of SY5Y cells stably
expressing 19-GFP or 56-GFP (Ding et al., 2002).

However, reduction of Mdm2

expression with Mdm2 antisense oligonucleotides did result in significantly more cell
death in untreated 56-GFP cells than in 19-GFP cells (Figure 6). Treatment of cells with
antisense oligonucleotides resulted in reduction of MDM2 expression of approximately
40% (Figure 6A).

Concomitant with this decrease in Mdm2 expression, there was

significant increase in cell death of 56-GFP cells compared to 19-GFP cells (Figure 6B,
C). There was also a small, but significant increase in cell death in 19-GFP cells.
However, the 56-GFP cells had approximately 5 times the cell death of 19-GFP cells.
With regard to HD, this could mean that, in the presence of polyglutamine expansion,
interactions between p53 and Mdm2 would be altered, possibly causing alterations to
p53 stability. Loss of Mdm2 leads to greater death in 56-GFP, suggesting that Mdm2
mitigates polyglutamine toxicity. A mechanism for this could be that through some
signaling pathway, p53 is stabilized in cells that express polyglutamine.

The

mechanism that stabilizes the protein by definition protects p53 from degradation,
probably by masking or modifying residues that are important for Mdm2 mediated
ubiquitination.

One glaring example of this are the C-terminal lysines that are

ubiquitinated. Acetylation of these sites could prevent the ubiquitination of these sites.

48

Mdm2 is a transcriptional target of p53; Mdm2 expression increases with increases in
p53 activity (Li, 2002 #1420).
Mdm2 can also mediate p53 interaction with DNA. Mdm2 associates with the
amino terminal of p53 in the same region that contains p53 DNA transactivation
domains (Oliner et al., 1993; Wadgaonkar et al., 1999) . This interaction can also
inhibit p53 interaction with other transcriptional coactivators such as the HAT proteins
(Grossman et al., 1998; Wadgaonkar et al., 1999).
In my studies, I found that p53 underwent modifications in vitro. These included
phosphorylation and acetylation in cells expressing pathological lengths of
polyglutamine. Multiple serine and threonine residues of p53 can be phosphorylated in
response to a variety of stimuli. (Ashcroft et al., 1999; Balint et al., 2001; Vousden,
2002; Woods et al., 2001; Xu, 2003). Phosphorylation of p53 has been associated
with increased p53 transcriptional activity and increased p53 stability (Ashcroft et al.,
1999; Li et al., 2002; Shieh et al., 1997). Phosphorylation at some sites may prevent
or attenuate a protein-protein interaction. Serine 15 of p53 lies within the region bound
by Mdm2 (Alarcon-Vargas et al., 2002). While the contribution of Serine 15
phosphorylation to the p53 –Mdm2 interaction is not completely understood, there is
consensus that this and neighboring sites probably contribute to both p53 stability and
localization (Ashcroft et al., 1999; Bargonetti et al., 2002; Shieh et al., 1997). It’s
thought that phosphorylation of this and/or nearby sites attenuates the p53-Mdm2
interaction (Shieh et al., 1997) . The p53 N-terminal nuclear export sequence (NES)
also lies within this region (Zhang et al., 2001). So phosphorylation of Serine 15 and/or
nearby sites may also serve to mask this site and promote p53 retention in the nucleus

49

(Zhang et al., 2001). In my studies, phosphorylation of p53 on Serine 15 was analyzed
in human neural cells expressing 19-GFP or 56-GFP. Though these experiments were
not normalized to some other protein such as actin, there was consistently more
phosphorylation at this site in 56-GFP expressing cells than in 19-GFP cells (Figure 7B).
Phosphorylation of p53 on Serine 15 occurs in response to UV radiation or other
inducers of DNA damage (Shieh et al., 1997). Oxidative stress has been associated
with DNA damage in HD (Bogdanov et al., 2001), and could play a role in the increase
in p53, possibly through phosphorylation of p53.
Acetylation of p53 occurs on 6 different lysine residues including 320, 373, 381
and 382 (Gu et al., 1997) (Grossman, 2001; Liu et al., 1999). The first site is acetylated
by P/CAF and the latter by p300/CBP. These HAT proteins typically are recruited to
specific promoters to acetylate amino terminal regions of the core histone proteins. This
results in decompression of the DNA from the nucleosome, allowing the transcriptional
machinery access to target genes. HAT’s also acetylate p53 and it is thought that this
also serves to recruit other transcriptional coactivators (Barlev et al., 2001; Chan et al.,
2001). Acetylation has been associated with increased transcriptional activity of p53,
and with stabilization of the protein (Balint et al., 2001; Grossman, 2001; Li et al.,
2002).
There was more acetylated p53 in 56-GFP cells than in 19-GFP cells (Figure
7A). It has been suggested that acetylation of p53 serves to stabilize p53 or increase its
transcriptional activity. Acetylation of p53 occurred on lysine 320, which is mediated by
P/CAF, as detected by a an antibody raised against p53 acetylated only on that
residue. P/CAF acetylation at lysine 320 was demonstrated to be inhibited by MDM2
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association with P/CAF in one study (Jin et al., 2002). Data from other studies found
similar relationships between p300 and Mdm2 (Ito et al., 2001). P/CAF is associated
with p300 and CBP, and all 3 proteins promote p53 transcriptional activity.
It is interesting to note that histone deacetylase inhibitors, as well as over
expression of CBP, have been shown to ameliorate some aspects of polyglutamine
neurotoxicity (McCampbell et al., 2001; Steffan et al., 2001; Taylor et al., 2003). This
is consistent with the hypothesis that neuronal dysfunction in HD is due to
polyglutamine expansion mediated alterations to transcription. CBP is a major part of
the transcriptional machinery, as it mediates acetylation of histones. CBP also
acetylates p53 (Gu et al., 1997), and this could reveal a role for p53 in the dysregulation
of transcription observed in HD. CBP contains a polyglutamine region and it has been
suggested that this region is important for interaction with mutant Htt. CBP binds to
phosphorylated CREB, which in turn binds to the cyclic AMP response element (CRE).
CBP serves to acetylate histones, thereby decompressing the nucleosomes and
allowing the transcriptional machinery to assemble at the appropriate promoter sites.
CBP, along with p300 and P/CAF, serve as “bridges” to the Pol II enzyme (Chan et al.,
2001) . Alterations to CBP function are most likely to cause disruptions to normal
transcription (Chan et al., 2001). Alterations to CREB and its regulators have been
found to cause neurodegeneration reminiscent of HD (Mantamadiotis et al., 2002).
Alterations of CRE- mediated transcription have been found in animal (Luthi-Carter et
al., 2002) and cell models of HD (Wyttenbach et al., 2001), as well as models of SBMA,
a polyglutamine disorder caused by expansion of the polyglutamine region of the
androgen receptor (McCampbell et al., 2000). Changes in CRE-mediated transcription
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can affect pathways involved in neural homeostasis. For example, Brain Derived
Neurotrophic Factor (BDNF) is regulated by CRE- mediated transcription, and was
found to be downregulated in human HD brain (Ferrer et al., 2000). BDNF has been
found to be important for neural homeostasis, and is up regulated by wild type htt
(Zuccato et al., 2001). Treatment of an inducible cell model with cAMP, the second
messenger that induces CRE mediated transcription, ameliorated some polyglutamine
dependent deficiencies in an HD cell model, including neurite outgrowth and cell death
(Wyttenbach et al., 2001). Interactions between CBP and mutant Htt have been
reported in several studies (Nucifora et al., 2001; Steffan et al., 2000; Yu et al., 2002).
In one study, almost complete sequestration was reported in cell models, mouse
models, and human brain (Nucifora et al., 2001). Soluble CBP was greatly reduced in
the brains of HD patients. Reduced CBP reporter activity was also reported in cell
models of HD and dentatorubral and pallidoluysian atrophy (DRPLA), another
polyglutamine disorder caused by polyglutamine expansion of atrophin-1. CBP over
expression rescued polyglutamine expansion cell death in cell models of both diseases.
Deletion of CBP resulted in pathology in cells expressing nonpathological lengths of
polyglutamine. In another study, CBP was also found to aggregate with mutant Htt in
cell and mouse models of HD (Steffan et al., 2000). This occurred concomitant with p53
interaction with mutant Htt. The mechanism of mutant Htt induced alterations to
transcription is somewhat controversial. Yu and colleagues found that even though
CBP may be co localized with mutant Htt in the nucleus, it was not however depleted
(Yu et al., 2002). This study suggested that CBP interacted with soluble mutant Htt,
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comparable to what was seen with SP1, which is another transcription factor that
contains a polyglutamine region.
Mutant Htt constructs have been shown to interact with p53 in one study (Steffan
et al., 2000). In this study, p53 aggregated with mutant Htt in intracellular inclusions
observed in cell models of HD. Mutant Htt co-immunoprecipitated with p53 as well as
with CBP. Mutant Htt interaction with p53 was independent of the proline rich region of
Htt in cells, although there was a requirement for the proline rich region in vitro.
Additionally, p53 interaction with mutant Htt required the C terminal region of p53, a
region that is highly regulated. For example, the NES domains and tetramerization
domains of p53 lie in this region (McLure et al., 1998). Interaction of mutant Htt with
p53 would alter p53 mediated transcription (Steffan et al., 2000). This same group
found that there was aberrant histone acetylation in cells that expressed a
polyglutamine expanded mutant Htt fragment. Treatment of animals transgenic for
mutant htt with HDAC’s alleviated the neurodegeneration observed. It was found that
HDAC’s also improved histone acetylation in these animals. These data gives pause
when one considers the effects maintaining acetylated sites on p53. If acetylated p53 is
active, and HDACs attenuate neurotoxicity, then active p53 in HD models may not be
detrimental to cells. Active p53 could be beneficial or may play no significant role in
vivo. This idea becomes more important when I discuss the in vivo studies I conducted.
Taken together, these data have lead researchers to investigate the use of
HDAC inhibitors in potential clinical trials. HDAC inhibitors have been found to alleviate
polyglutamine neurotoxicity in animal and cell models (Steffan et al., 2001). However,
in light of our studies, it is likely that HDAC inhibitors may adversely affect p53 function.
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HDAC inhibitors keep p53 acetylated and p53 mediated transcription active (Juan et al.,
2000). It was also found that use of HDAC enzymes reduced p53 interaction with the
BAX promoter. BAX has been implicated in neural death and mitochondrial dysfunction
(Fortin et al., 2001). This data suggests that inhibition of HDAC would promote higher
transcription of the BAX gene, which could be detrimental to neural homeostasis (Juan
et al., 2000). However, there was increased acetylation in 56-GFP cells compared to
19-GFP cells, but this has no effect on cell viability (Ding, 2002 #403).
The expression, stability, and localization of p53 were altered in differentiated 56GFP cells. Additionally, post-translational modifications were found to be increased in
56-GFP cells. Interactions between Mdm2 and p53 were found to be altered in 56-GFP
cells. Taken together, these data appear to support the hypothesis that p53 expression,
stability, and localization are altered in a cell model of HD. It remains to be seen what
the mechanism of p53 stabilization in 56-GFP cells is, and what the ramifications of p53
stability may be.

Polyglutamine Expansion Alters p53 Expression and Activity in neural cells
Transactivation of genes by p53 is dependent upon sequence-specific p53
interaction with DNA (Oren, 2003), so this data implies that p53 transcriptional activity
may be higher in 56-GFP cells compared to 19-GFP cells. However, this data only
demonstrated increased interactions in vitro. To determine if p53 DNA binding activity
had a role in polyglutamine mediated neurotoxicity, a cell line expressing a ts mutant of
p53 mutant was used (Hughes et al., 2000). This mutation has been found to greatly
inhibit p53 transcriptional activity, notably of p21Waf1/CIP1 protein, a protein responsible
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for growth arrest following treatment of cells with Nerve Growth Factor (NGF) (Hughes
et al., 2000).

Following treatment with NGF, cells that express ts p53 do not undergo

cell cycle arrest, but do differentiate into a neuronal phenotype (Hughes et al., 2000).
PC12 cells transiently transfected with 56-GFP were found to undergo cell death. Cell
death was greatly attenuated in cells that stably express ts p53 (Figure 9G). This data
indicates that transient transfection of cells with 56-GFP induces cell death that is
dependent on p53 transcriptional activity. The possibility that p53 could contribute to
neural death in other ways besides transactivation of genes was considered. Recent
studies have shown that a fraction of p53 localizes to the mitochondrion following
ionizing radiation, a classic inducer of p53, and binds with anti-apoptotic proteins of the
BCL-2 family of protein (Manfredi, 2003; Mihara et al., 2003). This in turn leads to
perturbations of the membrane and cytochrome C release, an event which precedes
apoptosis. This interaction also occurs through the DNA binding domain of p53, which
is interesting because ts p53 is deficient in DNA binding (Mihara et al., 2003). It may
prove useful to examine localization of p53 in the ts p53 cells. It might also prove useful
to show that in vector cells transiently transfected with 56-GFP, p53 promotes the
transactivation of pro-apoptotic genes such as BAX (Morrison et al., 2000) or APAF-1
(Fortin et al., 2001), and these p53 mediated actions are attenuated in the ts p53 cells.
The expression and localization of p53 were found to be altered in cells
expressing pathological lengths of polyglutamine compared to cells expressing
physiological lengths. The data indicate that polyglutamine expansion in this model
serves to stabilize p53. Polyglutamine expansion induced neurotoxicity which was
relieved by disabling p53 transcriptional activity (Figure 9). Taken together, the data
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agree with the hypothesis that polyglutamine expansion alters p53 expression,
localization, and activity. There was stabilized expression of p53 and higher levels of
modified p53 in 56-GFP cells compared to 19-GFP cells. There were differences in
p53-Mdm2 interactions and p53 localization in 56-GFP cells compared to 19-GFP cells.
Mdm2 expression was highest in 56-GFP cells but Mdm2 interactions seemed to be
lower than in 19-GFP cells. Reduction of Mdm2 expression resulted in cell death that
was much greater in 56-GFP cells than in 19-GFP cells. It would appear from the data
that a role for p53 in HD can be elucidated. Whether this role is mediation of neural
death in HD remains to be seen. It could be that p53 is not directly involved with neural
death in polyglutamine diseases. The data on this is very thin, but absence of p53 in a
mouse model of SCA1, another polyglutamine disorder, demonstrated absence of p53
did not affect cell number or motor performance (Shahbazian et al., 2001). However,
absence of p53 did reduce the amount of dendritic thinning seen in SCA1 mice.
Dendritic thinning, also known as dearborization, is typical of SCA1. This may reflect a
contribution of p53 to other pathways other than the well known apoptotic pathways.

p53 in the R 6/2 mouse
The experiments I’ve described served to investigate basic p53 biology in the
presence of polyglutamine expansion in vitro. In order to investigate the role of p53 in
HD in vivo, p53 and modified p53 expression were examined in R6/2 mice, a model of
HD, as well as in human HD brains. R6/2 mice express an N-terminal fragment of exon1
of the human HD gene containing a polyglutamine region of 145 residues in length
(Mangiarini et al., 1996). This mouse develops a pathology at 8 weeks that is

56

somewhat reminiscent of human HD. Starting at approximately 7 weeks of age,
intranuclear aggregates and inclusions within dystrophic neurites are observed in the
brains of R6/2 mice (Davies et al., 1997). However, neurodegeneration is not specific to
the striatum, but rather diffuse throughout the cortex and cerebellum as well. Changes
to nuclear morphology, including indentations of the nuclear membrane and an increase
in nuclear pore density have been observed (Davies et al., 1999). Similar changes to
nuclear morphology have been observed in human postmortem HD brain (Davies et al.,
1997). A later study found that there is non-apoptotic neurodegeneration that develops
late in life (14 weeks) (Turmaine et al., 2000). R6/2 mice also develop a progressive
neurological phenotype that includes clasping behavior (inability to splay when
suspended by the tail), and a movement disorder like that seen in persons with HD.
There is a loss of body weight as well as decreased brain size compared to wildtype
littermates. Contrary to data in the SY5Y model, p53 expression was markedly less in
the R6/2 mouse compared to wild type controls at 4 weeks and at 10 weeks of age
(Figure 9A). There was a slight decline in p53 expression at 10 weeks in HD mice
compared to 4 weeks (Figure 9A).
One explanation of the differences between the mouse and in vitro data is that
there are differences in the polyglutamine constructs used and that this may influence
interaction between p53 and polyglutamine expanded protein. In the SY5Y studies, the
constructs used was a fusion of GFP and a polyglutamine fragment (Ding et al., 2002).
In the R6/2 mouse, the construct is an N-terminal fragment of polyglutamine expanded
human mutant Htt. Suhr and colleagues used similar fragments fused to GFP to
demonstrate protein aggregation in human embryonic kidney 293 cells (HEK 293 cells)
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transfected with htt constructs (Suhr et al., 2001). When aggregates and cell lysates
were examined by Western blot, it was found that p53 aggregated with mutant Htt.
Additionally, it was found that the relative amount of sequestered p53 was
approximately 3 fold greater than soluble p53. The constructs were made preserving
the polyproline region downstream of the polyglutamine region of the htt fragment. This
region has been suggested to play a part in mutant Htt –p53 interaction in vitro (Steffan
et al., 2000). However, in cell culture systems, there was no such dependence on the
proline rich region. The proline rich region of p53 lies between amino acids 64 and 91.
Repression of transcription by exogenous p53 of a reporter gene (multi-drug resistance
gene or MDR-1, fused to luciferase) was examined by Steffan and colleagues in cells
that lack endogenous p53. They found that p53 effectively repressed transcription of
MDR-1. Interestingly, they found that mutant Htt fragments repressed MDR-1
transcription as effectively as p53. mSin3a has been shown to interact physically with
the N-terminal region of p53 through amino acids 40-160. This region contains the
transactivation domain and the proline rich region. Interaction of mSin3a with p53 has
been shown to prevent MDM2 mediated proteolysis of p53, thereby stabilizing p53
(Zilfou et al., 2001). Presumably this allows p53 to remain attached to promoters with
mSIn3a for a longer period of time. The interaction of p53 and mSin3a required amino
acids 61-75 of p53. This region lies within the proline rich region of p53, which is
essential for p53 mediated apoptosis. However, mSin3a was also found by Steffan and
colleagues to interact in vitro with mutant Htt in a polyglutamine length and Htt
polyproline region dependent manner, although this was a weak interaction. This could
explain the differences between the in vitro and mouse studies I’ve conducted. If
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mSIn3a interacts with mutant Htt in vitro, this could disrupt the mSin3a mediated
protection of p53 from Mdm2 directed proteolysis. If mSIn3a normally protects a
fraction of p53 protein from proteolysis, then disruption of the association would be a
likely avenue for decreased p53 in R6/2 mice. Mdm2 and p53 are both sequestered in
cell models of HD, (Suhr et al., 2001), so examination of relative levels of p53 and
Mdm2 would be useful in mice. Mdm2 was not examined in my analysis of R6/2 mice.
The GFP constructs used in the in vitro studies do not contain a proline rich region.
This could explain why there is more p53 in the 56-GFP cells, as these constructs lack
the region of mSin3a interaction. Experiments could be done in cell models of HD
expressing human htt N-terminal fragments. Experiments that might be informative
would be immunoprecipitation experiments to show interactions between p53 and
mSIN3a, p53 and Mdm2, and mSIn3a and htt. Differences in cells expressing
pathological and nonpathological polyglutamine expansion could be noted and
contrasted to parallel experiments with GFP-polyglutamine fusions. Additional
experiments could investigate mSIN3a’s effects on p53 stability in cells expressing
polyglutamine expansion similar to the mSIn3a –p53 interaction study (Zilfou et al.,
2001). If my proposed model is valid, then these data would show that p53 is less
stable in cells expressing pathological htt compared to cells expressing nonpathological
htt. This could help deduce why there is less p53 expression in HD mice than wild type
mouse, and help elucidate the role of p53 in HD neurotoxicity.
Phosphorylation of p53 at serine 392 has been shown to stabilize p53 tetramer
formation (Liang et al., 2001). Studies have indicated that p53 binds DNA as a tetramer
(McLure et al., 1998), and stabilization of this complex may help in preventing nuclear
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export of p53. In HD mice, p53 was phosphorylated on Serine 392 less than in wild
type controls (Figure 9B). There did not appear to be an age dependent change in
phosphorylation. Phosphorylation of p53 tended to correlate with p53 expression in HD
and wild type mouse, suggesting a possible contributing factor for p53 stability in HD
mice. In other words, when phosphorylation of p53 on Serine 392 is reduced, p53 is not
maintained as a tetramer, and p53 stability goes down. Another possibility is that in the
normal mouse brain, p53 levels are maintained at a low level that is sufficient to prevent
uncontrolled growth.

Acetylated p53 levels were similar in wild type and HD mice at 10

weeks. (Figure 9C). There was significant variability between the animals at 4 weeks,
making a strict interpretation difficult.

Human HD
In human HD brains, p53 expression was notably less than in control brains
(Figure 10A). This pattern was repeated for both phosphorylated and acetylated p53 as
well (Figure 10B and 10C, respectively). At first observation, it would appear that p53 is
down regulated in the caudate of HD brains. However, these brains were all of Grade 4
pathology. At this level of pathology, most of the neurons of the caudate have been lost
concomitant with greater astrogliosis (Vonsattel et al., 1985). Most of the neural tissue
is gone and there are approximately 30 % more astrocytes, which proliferate after or
during neurodegeneration. In control brains, there were marked levels of p53 as well as
modified p53 species. It must be noted that though p53 levels were barely detectable in
HD brain, phosphorylated and acetylated p53 were also detected at very low levels
compared to controls. This would imply that active, stable p53 is present in normal
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human striatum. One of the primary functions of p53 is to maintain genomic stability
and prevent aberrant growth (Oren, 2003). Interpreting the results in this experiment
(Figure 10) is difficult. Control brains are so different from HD brains with regard to
resident cells in the caudate, that p53 expression data may be irrelevant to the disease.
The data suggest that loss of p53 may bear responsibility for the neuropathology
observed, and that in its normal function, p53 is beneficial for the brain, as well as the
individual neuron. In vivo, p53 serves different roles depending upon cellular and
temporal context. Blood cells such as lymphocytes are removed from the population
through p53 dependent apoptotic death. During neurodevelopment, p53 mediated
apoptosis removes up to 50 % of the neurons from the brain (Miller et al., 2000).
Temporal and spatial distribution of p53 and p53 mediated pro-apoptotic genes are
varied in neurodevelopment (van Lookeren Campagne et al., 1998). PC12 neural cells
with Nerve Growth Factor (NGF) resulted in up regulation and nuclear localization of
p53. This was followed by a cell cycle arrest and neurite outgrowth (Hughes et al.,
2000). Using the ts p53 expressing PC12 cells used in my studies, they found that
neuritic growth is not dependent upon p53 DNA transcriptional activity, but that cell
cycle arrest is. This data suggests that one function of p53 is to prevent aberrant
reentry into the cell cycle, and that a neuron could remain differentiated even though
p53 was inactive. Inappropriate activation of some cell cycle components has been
reported in neurodegenerative disorders. A recent paper found that there is
neurogenesis in the HD brain, even in very pathological cases (Curtis et al., 2003). The
cells detected were neural progenitor cells. These cells proliferate and differentiate into
neurons. This has been observed in adult rat brains as well. If resident cells are
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proliferating, then p53 function and activity presumably would be decreased compared
to controls. In that case, given the low levels of p53 in the mature brain already
(Figures 9 and 10), p53 expression may fall below detectable levels.
To determine the role of p53 in the neurodegeneration of HD it would be
necessary analyze brains over the course of the disease. With the few brains analyzed
in this study, and given the ethical constraints of analyzing human samples, it would be
difficult to assess p53 levels in relevant portions of the brain during the course of HD.
However, lymphoblasts from HD patients have been used to analyze the effects of
mutant Htt during the course of the disease (Panov et al., 1999; Panov et al., 2002).
One study investigated the role of Htt mediated defects in mitochondrial calcium
homeostasis (Panov et al., 2002). These defects were seen in patients and mice early
in disease progression. They found that there was a lower mitochondrial membrane
potential in mitochondria isolated from lymphoblasts of HD patients and HD mice
compared to controls. This was associated with greater mitochondrial depolarization
which was inhibited by cyclosporine A that inhibits mitochondrial permeability transition
(MPT). Cells from HD patients were more vulnerable to MPT dependent apoptosis
There was a direct interaction between htt and the mitochondrion (Panov et al., 1999).
Perturbations of the mitochondrion are associated with oxidative stress, which is a key
factor in HD . Additionally, recent data have shown that p53 is also localized to the
mitochondrion, though the evidence for this is still emerging (Manfredi, 2003; Mihara et
al., 2003). Localization of p53 to the mitochondria of lymphoblasts from HD patients
might be useful to study. Regardless, the use of cells derived from human patients
would be useful to study p53 biology in the context of human HD. Experiments in these
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cells could include examining the role of p53 in oxidative stress in an HD background
and comparing that to normal patients. It may be that differences would not be seen
under basal conditions, but when the cells are under stress, i.e. staurosporine treatment
observed in the Panov study. Also, it may be possible to study changes in p53
expression and activity through the course of the disease. One of the caveats to
studying in vitro systems of HD is that most experiments last on the order of hours or
days. HD takes many years to manifest, and extrapolation of data from tissue culture or
even animal models may be difficult. One point made by Panov and colleagues (Panov
et al., 2002), was that mitochondrial changes in membrane potential in HD patients
were slight, but otherwise, mitochondria functioned normally in HD . A good example of
this would be in my in vitro studies. The expression of p53 was elevated in 56-GFP
cells, yet 56-GFP cells are as viable as wild type or 19-GFP cells (Ding et al., 2002).
However, transient transfection of PC12 cells with 56-GFP led to cell death which was
attenuated by overexpression of a p53 protein deficient in DNA binding. But if these
changes are over the lifetime of a human, especially in a neuron that has to function for
up to 100 years, then perhaps they could prove detrimental. Perhaps lymphoblasts from
HD patients could be used to shed some light on p53 biology in HD in humans.

p53 and oxidative stress
Oxidative stress has been implicated in several neurodegenerative disease
including HD (Bogdanov et al., 2001; Browne et al., 1999; Perez-Severiano et al.,
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2002). Evidence for a role for oxidative stress in HD has been found in human patients
(Browne et al., 1997; Polidori et al., 1999) , animal models for HD (Bogdanov et al.,
2001; Perez-Severiano et al., 2000), cellular models of HD (Wyttenbach et al., 2002),
and chemical models of HD (Kim et al., 2002; Tkac et al., 2001). Oxidative damage to
proteins, lipids, and DNA has been observed in all of these models (Bogdanov et al.,
2001; Matthews et al., 1998). Treatment of animals with the succinate dehydrogenase
inhibitors 3-NP or malonate has been shown to produce energy depletion in animal and
humans, as well as striatal lesions that are highly similar to those observed in HD.
Humans that have accidentally ingested 3-NP develop neuropathology similar to that
seen in HD. These toxins also lead to production of ROS. Hence 3-NP and malonate
have been used as experimental models of HD (Grunewald et al., 1999) . As further
evidence for the role of oxidative stress in HD, treatment of cellular (Wyttenbach et al.,
2002) or animal models of HD (Ferrante et al., 2000; Ferrante et al., 2002) with
antioxidants has been shown to ameliorate some of the pathology and neurophysiology
of the disease. In one study, for example, mice that expressed an N-terminal fragment
of polyglutamine expanded human htt (HD-N-171-82Q) were treated with the
antioxidant coenzyme Q10 (CoQ10). CoQ10 is an essential cofactor of the electron
transport chain and serves to neutralize ROS (Beal, 1999). Additionally, mice were
treated with remacemide, an N-methyl-D-aspartate (NMDA) receptor antagonist, which
was used because of its attenuation of the effects of glutamate excitotoxicity. Treated
mice outperformed untreated mice in motor skills, and that they had greater body
weight. There was no difference in survival between treated and untreated mice.
Another study investigated the effects of CoQ10 and remacemide on motor
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performance, survival, and brain weight in R6/2 mice. Motor performance was
improved with COQ10 or remacemide, or both in combination. Brain size is decreased
approximately 20% in R6/2 mice compared to controls (Davies et al., 1997). Brain size
was significantly increased in treated animals versus untreated mice, probably due to
reduced ventricle size (Ferrante et al., 2000). Enlarged ventricles are a characteristic of
R6/3 symptomatic brain and result from degenerative neurons. Metabolic impairment
has been linked to HD, and can result in the production of ROS (Browne et al., 1999).
Treatment of animals with creatine or cyclocreatine, substrates for creatine kinase, an
enzyme that regulates the ATP/ADP ratio in the brain, reduced metabolic dysfunction
and ROS production in 3-NP and malonate treated animals (Andreassen et al., 2001).
This was evidenced by lower levels of lactate production, reduced hydroxyl production,
and reduced levels of 3-nitrotyrosine, a marker of peroxynitrite mediated protein
oxidation.
HD is associated with increased oxidative stress (Browne et al., 1999;
Grunewald et al., 1999). Oxidative stress is associated with increased p53 expression
and p53 transcriptional activity in a variety of models of neural injury and disease
(Bates et al., 1999; Mattson et al., 2001). Taken together, this suggests a possible role
for p53 in HD neurotoxicity. In Chapter 3 I described research aimed at investigating
the hypothesis that alterations to p53 expression and/or activity mediated neural death
induced by oxidative injury. The expression of p53 was analyzed as well as the effects
of genetic and pharmacological inhibitors of p53 transcriptional activity on neural death
induced by H2O2. I did not investigate a direct role for oxidative stress neurotoxicity,
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but I did investigate the hypothesis that alterations to p53 expression and activity
mediated neural death induced by oxidative injury.
H2O2 induced dose dependent death in embryonic rat cortical neurons (Figure
11, 13). Analysis of p53 expression revealed elevated levels of p53 after 6 hours, with a
decrease in expression after 24 hours (Figure 12). This increase was noted with all
concentrations tested. There was some variation in the time course of p53 induction
between experiments. Specifically, in some experiments treatment with 10 µM H2O2
sometimes induced elevated p53 at earlier times than 1 µM H2O2.
Since the magnitude of p53 induction was similar for all concentrations of H2O2,
despite the dose dependent neural death, it is likely that neural death was not
completely dependent upon p53. Transcriptional activity of p53 has been in implicated
in other models of oxidative stress (Duan et al., 2002). Inhibition of p53 expression with
p53 oligonucleotides was shown to inhibit neural death following excitotoxic injury
(Lakkaraju et al., 2001). An inhibitor of p53, pifithrin-α, has also been shown to
ameliorate the effects of ischemia and excitotoxicity (Culmsee et al., 2001).
Cotreatment of H2O2 treated neurons with pifithrin resulted in attenuation of neural death
(Figure 13). There was not complete inhibition of cell death. This could be for various
reasons, including insufficient concentration of pifithrin, or production of survival factors
by other cells in the culture. There was no death attributed to pifithrin (Figures
13,14,15). The use of embryonic rat neuronal cultures was useful to study the induction
of p53 expression and cell death, as well as the establishment that cell death was at
least partially mediated by p53 transcriptional activity. However, there may be
differences in the role of p53 in rat and human. Also, the primary cultures utilized were
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of a mixed cell type nature, that is, they contained glial cells as well as neurons. Glial
cells, specifically astrocytes, are mitotic cells in culture, and the ratio of astrocytes to
neural cells was variable from experiment to experiment. And the induction of p53 in
mitotic cells in response to oxidative injury is probably dissimilar to that of neurons. This
is a possible source of variability in p53 expression data. To study the effects in a more
relevant model to human conditions, human neural SY5Y cells were used. This cell
line, derived from human neuroblastoma cells, are unique from many other types of
tumor derived cell lines in that they express wildtype p53.
Comparable to studies in primary cultures, H2O2 induced neural death in SY5Y
cells (Figures 15 and 16). Cell death was attenuated, but not abrogated by pifithrin in
undifferentiated cells. Likewise, in differentiated SY5Y cells, H2O2 induced a dose
dependent increase in cell death. Unlike differentiated cells, though, pifithrin blocked
cell death induced by 10 µM H2O2 (Figure 16). There are two possible reasons for this.
First, there could be differences in sensitivity of differentiated cells to pifithrin, compared
to undifferentiated cells. This was not tested. Second, differentiated cells may have
different pathways that are responsive to oxidative stress. There may be less of a role
for p53 in oxidative stress in undifferentiated neural cells. Taken together the data in
SY5Y cells demonstrated that p53 inhibition attenuates the cell death induced by
application of H2O2.
To corroborate data obtained with pifithrin, genetic inhibition of p53 was utilized.
In PC12 cells, the role of p53 transcriptional activity in response to oxidative stress was
investigated. In control cells, treatment with pifithrin resulted in a dose dependent
increase in cell death as determined by nuclear morphology and the MTT assay. Cells
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that over expressed ts p53, which was deficient in DNA binding, were resistant to this
cell death (Figures 16 and 17). This data suggests that p53 transcriptional activity has a
role oxidative stress mediated neural death. This distinction is important because it
shows that p53 was not acting in some other role besides as a transcriptional activator.
There are studies that have investigated p53 dependent apoptosis in the absence of
p53 transcriptional activity (Bates et al., 1999). For example, p53 interaction with antiapoptotic members of the Bcl family has been shown to promote the release of
cytochrome C from the mitochondrion (Mihara et al., 2003). There are also reports of
p53 interacting with other proteins, such as DNA helicases, which are involved in DNA
repair (Wang et al., 2001). It was found that p53 interacts with BLM, a DNA helicase
that is implicated in Bloom syndrome, a disease characterized by cancer disposition.
BLM interacted with the C-terminal region of p53. Disruption of this interaction results in
alterations to BLM function and aberrant growth, whereas deletion of the p53 DNA
binding domain did not. Hence, p53 but not p53 transcriptional activity was required for
apoptosis. The in vitro studies I conducted don’t support this type of interaction in p53
mediated apoptosis, as mutation of the DNA binding site attenuated cell death. If p53
mediated apoptosis was not dependent on transactivation of p53 dependent genes, but
rather helicase –p53 interaction, then cell death would not have been reduced in ts p53
cells unless the helicase mediated event was dependent upon p53 interaction with
DNA.
Taken together, the data presented in Chapter 3 suggests that p53 expression is
altered following oxidative injury, and that p53 activity is increased. This latter point was
determined indirectly, as no measurement of p53 mediated transcription, i.e. using p53
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reporter assays, was made. However, in the presence of ts mutant p53 protein, cell
death was largely abrogated. This data fits in well with other studies utilizing either
pharmacological or antisense approaches to elucidation of the role of p53 in neural
injury and death(Culmsee et al., 2001; Duan et al., 2002; Lakkaraju et al., 2001). In a
chemical model of Parkinsonism, treatment of mice with the mitochondrial toxin 1,2,3,6tetrahydropyridine (MPTP), results in the production of BAX, which is transcriptionally
activated by p53, as well as mitochondrial dysfunction and oxidative stress (Bates et al.,
1999; Duan et al., 2002; Morrison et al., 2000). BAX has been implicated in neuronal
death in several studies. In mice pretreated with pifithrin, MPTP induced BAX
production was decreased, and the mice had improved motor skills compared to mice
treated with MPTP alone. This study clearly implicated a role for p53 in oxidative stress
resulting from mitochondrial dysfunction (Duan et al., 2002). When treated with pifithrin,
neurons were protected from apoptotic death induced by glutamate, amyloid-beta (a
prime suspect in AD), and DNA damaging agents (Culmsee et al., 2001). Additionally,
mitochondrial dysfunction in neurons was attenuated by pifithrin following treatment with
these agents, and BAX production and p53 DNA binding activity were reduced. Taken
together these data fit with the in vitro studies I conducted. Pifithrin attenuated cell
death, suggesting that p53 was involved with H2O2 toxicity. This was true at all
concentrations tested and it was also true for all models tested, in both primary neuronal
cultures and human neural cell lines. These data were corroborated by the PC12 data
where it was demonstrated that over expression of ts p53 attenuated cell death.
Oxidative injury induced cell death and changes in p53 expression. These data
support the hypothesis that p53 plays a direct role in mediating oxidative stress toxicity.
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The details of p53 involvement remain to be worked out. Localization of p53 to the
nucleus is almost assumed, due to the dependence of cell death on p53 transcriptional
activity in primary neurons as well as in cell lines, but high resolution
immunocytochemistry would be informative.
Cell death in both 56-GFP PC12 cells and H2O2 treated cells was almost
completely blocked in cells expressing the mutant p53, indicating that neural death was
mediated by p53 transcriptional activity.. Oxidative stress has been implicated in HD
(Beal et al., 1994; Deckel et al., 2001; Schilling et al., 2001), and investigating the
mechanism of death in 56-GFP cells would be appropriate. Taken together, the data
demonstrates that p53 is altered in expression and activity in a model for oxidative
stress. Neural death is attenuated by inhibition of p53 transcriptional activity. The
possibility that a connection could be made between HD and p53 and oxidative stress is
intriguing.
Constructing a model that describes all the interactions between p53, other
proteins, and their effects on neural homeostasis would be a Herculean effort.
However, a possible model of the interactions between polyglutamine expansion,
oxidative stress, p53 and neural death associated with HD is presented in Figure 18.
Oxidative stress can both induce and is induced by p53 activity. Huntingtin has been
shown to interact with the mitochondrion. Mutant huntingtin has been shown to affect
mitochondrial homeostasis, which over the lifetime of a neuron could make it more
vulnerable to other stresses (Panov et al., 2002). Excitotoxic stress can also induce
p53, and excitotoxicity has been suggested to have a role in HD
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Figure 18. There are many possible routes to HD through p53.
Polyglutamine expansion, oxidative stress, and other stresses can activate
p53 through upregulation or stabilization. Oxidative stress can occur by p53
dependent or independent means. p53 can be stabilized by inhibition of
Mdm2. The activity of p53 can be increased through phosphorylation and/or
acetylation of p53 (P,A). Mitochondrial dysfunction is associated with
oxidative stress and is possibly induced by polyglutamine expansion.
Oxidative stress eventually can lead to neural death.

(Sieradzan et al., 2001; Uberti et al., 1998). A direct role for p53 in HD is difficult to
elucidate at this point. My studies have shown that p53 is stabilized in neural cells
expressing polyglutamine-GFP fusion proteins. Levels of modified p53 were higher in
cells expressing 56-GFP than in cells expressing 19-GFP. Mdm2 expression and
nuclear localization was higher in 56-GFP cells, yet interaction with p53 was decreased
compared to 19-GFP cells. Transient transfection of neural cells with 56-GFP induced
neural death. This was attenuated by inhibition of p53 activity. Oxidative stress
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mediated neurotoxicity was also attenuated by inhibition of p53 activity. These data
together suggest a link between oxidative stress, p53, and polyglutamine neurotoxicity
in an indirect way. Further investigations will need to be done to dissect these
interactions so that a more complete model can be elucidated.

Future Directions
The role of p53 in polyglutamine disorders was not elucidated in these studies,
though some qualified statements can be made about p53 biology in a variety of
polyglutamine expansion models. Two hypotheses were tested in my studies. First,
polyglutamine expansion induces alterations in p53 expression, stability, and activity.
Second, p53 plays a direct role in mediating some aspects of oxidative stress, which is
relevant to HD.
To investigate the first hypothesis, the expression of p53 and modified p53 was
examined in 4 different models of HD, 2 in vitro and 2 in vivo. These were a human
neural cell model utilizing different lengths of polyglutamine fused to GFP, a rodent
neural cell model, the R6/2 mouse model, and human HD brain. The expression of p53
was altered in each of these models; however, the alterations investigated were
different from model to model. Transcriptional activity of p53 was implicated in neural
death induced by transient transfection of 56-GFP. Expression of p53 in 56-GFP cells
was more stable than in 19-GFP cells, even in the absence of increased p53 mRNA in
differentiated 56-GFP cells. In the absence of protein synthesis, p53 was more stable in
56-GFP cells, indicating that there could be less proteolysis of p53. Mdm2 has ubiquitin
E3 ligase activity and is a potent negative regulator of p53. Mdm2-p53 interaction was
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decreased in 56-GFP cells even though Mdm2 was up regulated and localized to the
nucleus. Treatment of 19-GFP and 56-GFP cells with Mdm2 antisense oligonucleotides
caused increased cell death in both 19-GFP and 56-GFP cells, but with much greater
death in 56-GFP cells (Figure 6). I described differences between the polyglutamineGFP constructs I used and those used in other investigations that implicated p53 in HD
(Steffan et al., 2000; Suhr et al., 2001). Future investigations could look at
modifications to p53 in an htt background and how mutant Htt may or may not affect
p53 activity.

Future studies should investigate which pathways were induced in the PC12 cells
by 56-GFP and mediated by p53. Assays for BAX or APAF-1 expression (mRNA or
protein or both), both p53 mediated genes, could be utilized in the existing PC12 cells
lines. In a chemical model of HD, p53 expression was found to be induced (Qin et al.,
1999). To show that p53 mediated transcription was altered by oxidative stress,
antioxidants could be used. If oxidative stress did induce p53, perhaps through DNA
damage, then use of these reagents, such as coenzyme Q10, would attenuate
production of these proteins. Another possibility would be to examine mitochondrial
function in mutant p53 and control PC12 cells after transfection with 56-GFP.
Mitochondrial membrane potential has been shown to be altered in lymphoblasts from
HD patients (Panov et al., 2002), so it may be useful to tie dysregulation of mitochondria
in with p53 in human HD lymphoblasts, or another cellular model of HD.
The expression of p53 protein was found to be altered in neural cells that were
treated with H2O2. Whether this was due to induction of p53 or stabilization of p53 was
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not determined. The role of Mdm2 was not investigated with regard to oxidative stress,
but would need to be determined in future studies. Post-translational modifications
would also be useful to study. These studies would reveal the regulatory elements of
the p53 mediated response. As discussed for the 56-GFP cells and PC12 cells, H2O2
induced cell death could be studied in more detail with regard to p53. It is clear that p53
transcriptional activity had a role in H2O2 induced neural death. It would be useful to
know the pathways .
Pharmacological inhibitors of p53 have been used in cancer research. The
original study that described pifithrin found it to inhibit p53 dependent apoptosis
following treatment with anti-cancer drugs or UV radiation (Komarov et al., 1999).
Pifithrin has also been found to ameliorate some effects of neural injury and oxidative
stress in vitro and in vivo (Culmsee et al., 2001; Duan et al., 2002). Quinolinic acid
(QA), an NMDA receptor agonist, induces an HD like neuropathology, including striatal
lesions in rats and man. QA has been shown to induce oxidative stress in animals and
in vitro cell cultures that is alleviated by antioxidant therapy (Cabrera et al., 2000). QA
was also found to induce p53 and p53 responsive genes in rats (Qin et al., 1999).
Possible studies could investigate pifithrin mediated protection in QA treated rats.
Pifithrin treatments could be given with and without antioxidant therapy. If some
oxidative stress induced by QA is p53 independent, then there should be at least an
additive effect with both treatments. Survival and behavioral studies could lead to
estimations of the gross contribution of p53 to HD neurophysiology and
neurophysiology. More detailed neuropathological examination could reveal other
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facets of the role of p53 in this model of HD.. For example, there may be less neural
death in animals treated with pifithrin.
Similar studies could be conducted using transgenic mice such as the R6/2. The
data obtained in the present studies indicate less p53 protein expression in R 6/2 mice.
However, this study did not address p53 activity in vivo. One way to do that would be
the use of pifithrin. If p53 activity were important in disease pathology and/or
physiology, then use of pifithrin may result in a decrease of neural atrophy observed in
these animals. We have obtained very preliminary data in this area. Pifithrin treated R
6/2 mice did not survive as long as untreated R 6/2 mice. Interestingly, wild type mice
treated with pifithrin lived and seemed unaffected. The mechanism of pifithrin mediated
death in R 6/2 mice is unclear, but a recent paper by Komarova and colleagues
demonstrated pifithrin mediated reductions in the heat shock response and
glucocorticoid signaling in mice and in vitro (Komarova et al., 2003). They found that
these reductions were p53 independent. Some connection has been made between the
heat shock response, polyglutamine disorders, and glucocorticoid signaling have been
made (Komarova et al., 2003). The data here is emerging, but perhaps with further
investigation, we will be able to determine the cause of death in the R6/2 mice treated
with pifithrin. An intriguing possibility is that pifithrin will help reveal beneficial activities
of p53 in the HD mouse.
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Chapter Five
Materials and Methods
Cell Culture
Cortical neurons were isolated from embryonic day 18 (E18) Sprague-Dawley
rats as previously described (Keller et al., 1999). Briefly, brains were removed from the
embryos, stripped of meninges, and rinsed with twice with minimal essential medium
(MEM). Brains were incubated in 0.25% trypsin for 10 minutes at 37 oC. Dissociated
brains were triturated with a 10 mL pipette, filtered through a 40 µm cell strainer, and
brought to 50 mL with complete medium. Complete medium consisted of 60% medium
A (Neurobasal medium supplemented with B-27 and 1% (v/v) penicillin/streptomycin)
and 40% medium B (MEM supplemented 2% (v/v) fetal bovine serum (FBS), N2
supplement, and 1% (v/v) penicillin/streptomycin). Brains were then pelleted by
centrifugation at 1000 x g for 5 minutes. Pelleted cells were then resuspended in
complete medium at 1 brain/mL of medium. Cells were plated at appropriate density on
35 mm, 60 mm, or glass-bottom 35 mm dishes that had been previously coated with
polyethyleneimine (PEI). After 2 hours, the medium was replaced with fresh complete
medium. Experiments were conducted after 5 days incubation in a 5% CO2 incubator
(37 o C) to allow neurons to achieve post-mitotic neuronal phenotype.
Neural SH-SY5Y cells were purchased from American Type Culture Collection
(ATCC) and stably transfected with 19Q-GFP and 56Q-GFP constructs (Moulder et al.,
1999), kindly provided by Dr. Eugene Johnson (Washington University), as previously
described (Ding et al., 2002). Cells were maintained in a 5% CO2 incubator (37 o C) in
MEM complete medium (Minimal Essential Medium, 10% (v/v) FBS, 1% (v/v)
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penicillin/streptomycin, and 800 µg/mL G418). For wild-type cells, G418 was omitted
from the medium. Cells were incubated for 5-7 days in retinoic acid, in order to
differentiate into post-mitotic neuron phenotype. All cells utilized were of fewer than 15
passages. . For antisense treatment, cells were incubated with either MDM2 antisense
(5´-GTT GGT ATT GCA CAT TTG CCT GCT C-3´; 50 nmol), or scrambled
oligonucleotide (5´-TCT AAG TGT CGC TTA CTG GTC TGT C-3´; 50 nmol), and
analyzed for MDM2 expression or cell death 24 hours following application.
PC12 cell lines were kindly provided by Dr. Kenneth E. Neet (Finch University of
Health Sciences, Chicago Medical School). The cell line stably expressed a
temperature sensitive (ts) mutant p53 engineered in the lab of Dr. Moshe Oren
(Weizmann institute of Science, Rehovot, Israel) that is defective in DNA binding. The
ts p53 gene was inserted into a retroviral vector under control of the cytomegalovirus
promoter. The control cell line was stably transfected with retroviral vector without any
insert (Barak et al., 1992; Hughes et al., 2000). At restrictive temperature, 39 (oC),
mutant p53 is overexpressed, and acts a dominant negative, abolishing wildtype
activity. Cells were maintained as described (Hughes et al., 2000). All experiments
described were conducted at the restrictive temperature.

HD Mouse Model
The R6/2 transgenic mouse model was used. This mouse expresses mutant
human huntingtin (htt) that contains ~1kb of human HD promoter region, exon 1 that
carries the CAG-repeat expansion unit (Davies et al., 1997; Mangiarini et al., 1996).
These mice have polyglutamine repeats of 141 to 157 repeats. They have a
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progressive phenotype with disease onset at approximately eight weeks. Mice younger
than this exhibit limited neuropathology, including decreased brain weight, and htt
immunoreactivity in the nuclei of cortical brain and striatum. After age eight weeks,
these mice develop the characteristic movement disorder of HD: resting tremor, abrupt
shuddering movements, and seizure. They also develop a progressive
neurophysiology and neuropathology including striatal nuclear inclusions, ubiquitin
immunoreactivity, and nuclear membrane perturbances. However, this neuropathology
is not as specific as in human HD. Degenerate, but not dead neurons, have been
reported in both cortex and striatum (Turmaine et al., 2000). For experimentation,
brains were removed from euthanized mice and immediately cooled on dry ice. Brains
were stored at -80oC until use.

Human Tissue
Samples of caudate from HD brains and control brains (n=4) were obtained from
the Harvard University Tissue Bank. Brains had a postmortem interval of 18-24 hours.
Samples were stored at -80oC.

Analysis of Protein Expression
To study the stability of p53 in polyglutamine expressing cells, cells growing in
60mm dishes were treated with 10 µM cyclohexamide to halt protein synthesis. Cells
were collected after 0, 5, 30, or 60 minutes, and p53 expression levels determined by
Western blot analysis. Adherent cells were scraped and collected in ice–cold
phosphate-buffered saline (PBS) - containing protease inhibitor mixture (Western blot
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buffer), and phosphatase inhibitor as described previously (Ding et al., 2002). For
analysis of brain tissue, a section was removed from the cortex (mouse) or caudate
sample (human) and solubilized in Western blot buffer after being ground with a Dounce
homogenizer. After determination of protein content, 50 µg of proteins were loaded onto
a 7.5% polyacrylamide (50 µM Tris-HCl) gel and run at 100V for 60 minutes. Proteins
were transferred to a nitrocellulose membrane at 100V for 60 minutes. After blocking at
room temperature in 5 % nonfat milk in TBS –Tween -20, blots were incubated in
primary antibody (1:1000) overnight at 4oC. Phosphorylated p53 was detected in SY5Y
cells with an antibody that recognizes p53 phosphorylated on Serine 15.
Phosphorylated p53 was detected in lysates from mouse or human brain samples using
an antibody that recognizes p53 phosphorylated on Serine 392. Acetylated p53 was
detected in all models studied using an antibody that recognizes p53 acetylated on
Lysine 320. Blots were washed in TBS-Tween-20 and then incubated in peroxidase
conjugated secondary antibody (1:7500) for 1 hour. The blots were washed in TBSTween-20 and antibodies detected by Enhanced Chemiluminesence (ECL).
To determine relative expression levels, intensity of bands corresponding to the
protein of interest were measured using Scion Image software. To determine percent
control intensity, band intensities were divided by the intensity of the relevant control
band (i.e. 0 hours) and that quotient multiplied by 100. To determine percent of Mdm2
interaction with p53, Mdm2 band intensities were divided by the intensity of the
unprecipitated Mdm2 band (Non-IP from 56-GFP cells) and then divided by 4, as there
was 4 times as much total protein that was immunoprecipitated as unprecipitated 56GFP protein analyzed.
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Immunoprecipitation
Neural SH-SY5Y, 19-GFP, or 56-GFP cells were collected in Western blot buffer.
A total of 200 µg protein was suspended in 250 µL Western blot buffer and incubated
for 2 hours with 3 µL precipitating antibody. A total of 25 µL of Fast Flow 4 SepharoseProtein G beads was added to the suspension and then rocked at 4 oC overnight. All
subsequent steps were conducted at 4oC. The beads were washed 3 times in Western
blot buffer, and then resuspended in protein loading buffer. After boiling for 5 minutes,
the beads were pelleted and proteins loaded on a 7.5% polyacrylamide gel. After
electrophoresis, proteins were transferred to a nitrocellulose membrane and then
blocked in 5 % nonfat milk (TBS- Tween-20) for 1 hour at room temperature. Blots were
incubated overnight at 4oC with antibodies diluted 1:1000 in 5% nonfat milk (TBSTween-20). After washing 3 times in TBS-Tween-20, blots were incubated in secondary
antibody (1:7500) for 1 hour at room temperature. After washing, proteins were
detected by ECL.

Immunostaining
To analyze localization of the protein of interest, immunostaining was performed.
Cells grown on glass bottom dishes were fixed with 4% paraformaldehyde in PBS (10
minutes), and permeabilized with TritonX - 100 (0.002%). After washing and blocking
steps (2% Horse Serum (v/v) in TBS), cells were incubated with primary antibody
(1:500) overnight. After further washing steps, were incubated with biotin-conjugated
secondary antibody (1:500) for 1 hour. Following washing of the cells, and incubation
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for 1 hour with ABC complex containing horseradish peroxidase, antibody was detected
using DAB. Cells were visualized on a Zeiss Axiovert 200 microcope using bright-field
and phase-contrast microscopy.

Analysis of Neural Death
To determine neural survival, nuclear morphology was assessed. In the last hour
of treatment, cells were treated with 1 µg/mL Hoechst 33342 stain, and visualized
fluorescently using a Zeiss Axiovert 200 microscope. Cells with fragmented or
condensed nuclei were considered to be nonviable. At least 300 cells in at least 6
dishes were counted in each experiment and the percentage of nonviable cells
determined. Cells with no treatment (i.e. empty vector or no treatment) served as
control. Mean and standard error were determined for at least 6 cultures.

p53 binding activity and neurotoxicity
To analyze the role of p53 DNA binding activity in polyglutamine neurotoxicity,
PC12 cells expressing a mutant p53 ( ts p53) were utilized. Cells were plated on PEI
coated glass-bottomed 35 mm dishes and maintained for 2 days in PC12 at 39 oC in a
5% CO2 incubator. Cells were then transiently transfected with 6 µg of the 56-GFP
plasmid as described previously (Ding et al., 2002). Briefly, plasmid DNA was
suspended with Lipofectamine reagent in OptiMEM and incubated for 1.5 hours at room
temperature. The medium was removed from the cells and replaced with OPTI-MEM
prior to addition of plasmid DNA. The cells were incubated at 39oC for 4 hours and then
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the medium replaced with DMEM complete medium. After 48 hours, cells were treated
with Hoescht 33342 stain and their nuclei visualized using fluorescence microscopy. At
least 300 cells in at least 6 dishes were counted in each experiment and the percentage
of nonviable cells determined. Cells with mock treatment (i.e. incubated with OptiMEM
alone) served as control.
Neural survival of PC12 cells was also analyzed by the MTT cell viability assay.
The MTT assay measures the reduction of MTT [(4, 5-Dimethylthiazol-2-yl)-2, 5diphenyltetrazolium bromide], which produces a blue-violet color. The ability of cells to
reduce MTT is a measure of cell viability. Growing neural cells were incubated with 0.1
mg/mL MTT for 1 hour. After removal of medium, cells were lysed with dimethyl
sulfoxide (DMSO), transferred to a 96 well plate and their absorbance read in duplicate
at 595 nm on an absorbance plate reader. Cells with no treatment served as control
and their mean absorbance set at 100% viability. Mean and standard error were
determined for at least 6 cultures.

Statistical Analysis
For experiments where neural death or cell survival was quantified, the mean
and standard error of the mean for each experimental group were calculated.
Differences between experimental groups were considered significant when p < 0.05 as
determined by the student’s t-test.
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